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ABSTRACT
Firms have increasingly offshored manufacturing to foreign countries in the
past decades due to the expected benefits driven by low manufacturing costs in
developing economies. With changes in competition and government pressure for
domestic production, however, manufacturing firms have reevaluated these decisions
leading some to reshore manufacturing activities. Recent studies have investigated
various reshoring motivations and developed conceptual frameworks that can be used
as tools in reshoring decisions. However, the complexity in decision making remains
high due to product and industry specific traits impacting the manufacturing process.
Examples include the increasing concern over product quality and changing
regulations. Two industries that are heavily impacted by reshoring decisions are
medical device and pharmaceutical companies. Theoretical support for these decisions
have been limited with most studies relying on Transaction Cost Economics (TCE)
and Resource Based Review (RBV). While valuable, these theories are insufficient to
explain the growing number of decision variables involved in reshoring. This study
proposes that Dunning’s ownership, location, and internalization (OLI) framework
explains more of the recent decision variables related to reshoring. Based on four subparadigms of the OLI framework, this study develops a reshoring decision model
using a systematic literature review (SLR) and semi-structured interviews. Then, the
study tests the model using a large-scale survey. Results show that reshoring decisions
in the medical device and pharmaceutical industries are dominated by quality and
regulatory requirements that involve long and complex validation processes, among
others. Lastly, using authentic industry parameters in an analytical model, this study

demonstrates the impact of reshoring and offshoring cost factors on reshoring
decisions. Managerial and theoretical implications are discussed.
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INTRODUCTION
Research background
Defined as “moving manufacturing back to the country of its parent company”
(Ellram, 2013, p.3), reshoring decisions are gaining interest in recent years as a
strategic economic activity for businesses with corresponding societal benefits. In that
sense, reshoring can be viewed as an activity that supports organizational
sustainability according to the triple bottom line (TBL) framework by Elkington
(1994), which includes economic, social, and environmental sustainability. Yun et al.
(2019) find that current studies on the interaction between economic and social
performance have a narrow focus on charitable corporate social responsibility (CSR)
activities because of the difficulty in developing measures for social performance. The
limited scope of social performance relies on the benevolence of corporations, for
example, ranging from cash donations to assignments of company resources to
charities. It often does not associate CSR with an outlay of resources contributing to
economic performance at the firm level. However, corporate consideration of
reshoring can be understood as an important strategic decision that improves an
organization’s economic sustainability that leads to business continuity as well as
social sustainability. Thus, a company’s reshoring decision to increase profitability
can also improve social performance by supporting local suppliers, for example,
(Ashby, 2016) and thus by creating employment opportunities in society.
Job creation and tax benefits are considered positive impacts of reshoring by
improving the lives of stakeholders in home countries that support domestic
production. This may be particularly true for manufacturing companies in the
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healthcare industry which provide products that have a critical impact on human wellbeing and revenue generation. These firms have increasingly outsourced
manufacturing to foreign countries due to the expected benefits driven by low costs in
developing economies. However, with changes in the internal and external
environment and government pressure for domestic production, some manufacturing
firms have reevaluated their offshoring decisions and reshored manufacturing. Recent
studies have investigated various reshoring motivations and have developed
conceptual frameworks that can be used as tools in reshoring decisions. However,
these tools are limited due to the increasing complexity in decision making driven by
product and industry specific traits. In healthcare, pharmaceutical and medical device
companies are hugely impacted, especially around product quality and changing
regulations.
When a firm considers reshoring, there are three possible outcomes:
1) Full reshoring: where a firm moves all production back to a home country;
2) Partial reshoring: where a firm moves only partial production back to a home
country while keeping the remainder in the foreign location(s); and
3) No Reshoring: where a firm keeps all production in a foreign location(s).
Given rational economic models, a firm will select the option that provides the
greatest benefit. The outcome that achieves the best performance is referred to as
“right-shoring” (Tate and Bals, 2017; Joubioux and Vanpoucke, 2016). Right-shoring
involves a review of a company’s “shoring” options for repositioning manufacturing
to meet firm objectives (Tate and Bals, 2017). This process involves a consideration of
the original offshoring motivation as well as reshoring drivers that may differ from the
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original offshoring decision. This decision requires a deeper understanding of both
qualitative and quantitative variables in the decision process. Thus, this study attempts
to investigate the factors that are considered in reshoring decisions and how these
factors can lead to right-shoring. A better understanding of these decision making
factors will improve organizational sustainability based on the social and economic
contribution of companies.

Research questions
The purpose of the study is to examine factors that impact manufacturing
reshoring decisions in the context of the healthcare industry and investigate how
reshoring can contribute to a right-shoring decision. This study achieves this goal by
answering the following research questions:
•

What factors impact manufacturing reshoring decisions in the healthcare
industry?

•

How do these factors impact reshoring decisions of medical device and
pharmaceutical companies?

•

What is an optimal right-shoring solution?

By answering these questions, this study makes contributions to the literature in
four areas. First, it is the first study to develop and empirically test a decision model
for reshoring in the context of medical devices and pharmaceuticals. The extant
literature suggests that variables impacting reshoring decisions vary from firm to firm,
product to product, and thus firm and product specific approaches are needed to
understand reshoring factors. Second, this study treats reshoring as an investment
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decision based on Dunning’s ownership, location, and internalization (OLI)
investment framework (Dunning, 1980). The study empirically examines why
companies consider reshoring decisions that can differ from their original offshoring
decisions. This provides a theoretical lens to see reshoring as a strategic location and
sourcing decision without treating reshoring simply as a temporary condition driven
by short-term cost benefits or immediate political and economic stability. Third, this
study also suggests that reshoring results in a positive interaction between economic
and social variables that improve sustainability without reliance on CSR or charitable
activities. Fourth, based on the results of the interviews and survey, a rudimentary
analytical model demonstrates how right-shoring can lead to optimal solutions for
reshoring manufacturing in healthcare. This model is a practical tool that uses
transportation cost as a differentiator that impacts reshoring decisions by examining
the balance between offshoring and reshoring. It shows that an optimal balance may
exist to inform right-shoring decisions.

Multi-method approach
To answer the research questions, this study uses multiple methods including:
1) Systematic literature review (SLR)
2) Semi-structured interviews
3) Large-scale survey
4) Rudimentary analytical model
An overview of how these methods are used is described sequentially in Figure 1
followed by a detailed explanation of the procedure.
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First, a systematic literature review (SLR) is conducted to identify current
research gaps and the existing variables that are used in reshoring decisions. The
identified variables are categorized based on a theoretical framework and developed
into a conceptual model. Since the topic of reshoring is still exploratory, a series of
semi-structured interviews is conducted with practitioners in the medical device and
pharmaceutical industry to identify new variables relevant to this research. The
interviews are continued until theoretical saturation is reached (Robinson, 2014).
Theoretical saturation is the point where no new information is being discovered
through data collection, in this case interviews (Suddaby, 2006). The topic is
theoretically saturated with knowledge. It is “theoretical” because it is practically
impossible to demonstrate that all knowledge is captured through any methodology.
The variables found in the interview process are incorporated into the conceptual
model and some parameters are eventually used in an analytical model.
To empirically test the conceptual model of reshoring factors, a large-scale
survey is employed using Dillman’s (2009) approach. This procedure contains four
steps: Step 1 (S1) - survey development, Step 2 (S2) - pre-test, Step 3 (S3) - pilot-test,
and Step 4 (S4) - administration (see Figure 1). A questionnaire is developed based on
the literature and the conceptual model. The initial questionnaire includes questions on
demographic information and 65 items from the conceptual model. Four questions on
product complexity, product standardization, technology intensity, and labor intensity
are added to measure product characteristics.
Then, the survey is pre-tested for readability, face validity, and content validity
on a group of academics and MBA students (Pre-test 1).
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Figure 1. Description of methodological procedure
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Many revisions are recommended to an extent where a second pre-test is warranted
(Pre-test 2). After the revisions are made, the second pre-test is conducted on a group
of 14 mid-level managers and scientists in the medical device and pharmaceutical
industries. As recommended by Dillman (2009; 2014), the second pre-test is
conducted in the presence of the researcher so that body language can be observed and
the respondents can ask questions and provide oral feedback. To facilitate this, Pre-test
2 includes a group debriefing assessment which identifies major issues demanding a
reevaluation of the measurement items and topic clarification (Ruel et al., 2016). The
participants reported that,
1) while the variables and factors reflect their experience, some of the
conceptual associations between the variables and factors are incorrect;
2) the survey is too long at 65 questions, driven by too many redundant items
measuring variables that can be measured by single items; and
3) the questions are too wordy and description of variables can be simplified
because the instrument will be delivered to professionals in the field.
To correct associations between the variables and factors, a multi-round Q-sort
is conducted with the Pre-test 2 group using a Delphi approach (McKnight, 2008;
Brady, 2015), which is recommended as a method to assess reliability and construct
validity at the pre-testing stage (Nahm et al., 2002). A Delphi systematically allows
participants to see and hear the responses of others when classifying variables and
their relationships. As a result, the group reclassified the 65 indicators into 15 different
categories, and items with unnecessary redundancy were reevaluated and excluded,
resulting in a reduction of the instrument to 54 indicators (items); 15 categories were
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the higher order grouping variables while the 54 were individual reshoring drivers.
This reclassification allowed for refutability of the variables that do not conceptually
associate with the theoretical framework. A second round of Delphi sought consensus
on classification. The 19 indicators that did not achieve over 75% of agreement
(McKnight, 2008) in the process were dropped. After another round of revisions based
on the dropped items, a new survey instrument containing 35 items was tested again
on the same Pre-test 2 group. No further revisions were recommended.
To minimize potential sampling bias due to the convenience sample for Pretest 2, a pilot-test is then performed on the new 35-item instrument with a new group
of 16 respondents from the medical device industry and 14 respondents from the
pharmaceutical industry. Unlike the Pre-test 2 group who work for a company that
manufactures both pharmaceutical and medical devices that used complimentary
technologies, the pilot-test group work for companies that only manufacture one or the
other. The results of the pilot-test lead to a minor revision to the introductory
statements and no changes to the 35 items. Due to only minor revisions to the
instrument, a second pilot-test is deemed unnecessary.
The final survey is administered online to mid-to-upper level managers and
technical personnel in medical device and pharmaceutical manufacturing firms in the
U.S. Since there are no substantial revisions to the instrument resulting from the pilottest group, the pilot-test responses are retained as part of the full sample. The first 30
responses from the final survey sample are compared with the pilot-test responses. A
simple correlation was used to compare the two samples. The correlation between the
two groups is significant at r = .60, suggesting that methods bias is not affecting the
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responses. It is important to note that approximately 50% of usable responses are
collected directly by the researcher while 50% of usable responses are collected
through a research firm that charge a fee for their services.
Lastly, a rudimentary analytical model is developed based on real-world
parameters collected during the interviews. The model demonstrates how to
quantitatively optimize a right-shoring decision when faced with both domestic and
foreign production options. The model uses parameters from a real medical device
company based on assumptions that are context specific.
The rest of this study is organized as follows. Section 2 presents the
methodology and the result of the systematic literature review, which is followed by
semi-structured interviews in Section 3. The measurement model is tested using a
survey and the results are discussed in Section 4. In Section 5, an analytical model for
right-shoring is proposed. Conclusion, limitations, and future direction of this
dissertation are discussed in Sections 6 and 7. As a result, this study suggests how
reshoring can be used as a strategic “right-shoring” decision for medical device and
pharmaceutical companies.

9

LITERATURE REVIEW
Defining right-shoring
Studies (Hilletofth et al., 2019; Tate and Bals, 2017; Joubioux and Vanpoucke,
2016) use the term “right-shoring” in relation to recently increasing reshoring
activities used in strategic location decisions that originated from offshoring. Likewise,
the term “right-shoring” in this research refers to location decisions based on
estimating the balance of domestic versus foreign (offshored) production to achieve
corporate objectives. While the first part of the study focuses on reshoring as the
reverse strategic decision to offshoring, the later part of the study demonstrates, based
on this understanding, how reshoring can be considered a right-shoring decision using
an analytical model.

Theoretical background
As a theory in international business, the ownership, location, and internalization
(OLI) framework, also known as the eclectic paradigm, was initially developed by
Dunning (1973) to explain foreign direct investment (FDI) and foreign activities of
multinational enterprises (MNEs). Dunning (1973) developed the theory to explain
why firms invest overseas and what determines the amount and composition of
international production. The OLI framework explains that three determinants are
considered in internationalization impacting propensity to engage in foreign
production: ownership advantages, location advantages, and internalization advantages.
Ownership advantage is the possession of a certain valuable, rare, hard-to-imitate, and
an organizationally embedded resource that allows a company to have a competitive
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advantage. Location advantage is the advantage associated with particular locations
that are separate from ownership advantages which may or may not be transferable
from the locations or can be combined with products in a home country.
Internalization advantage is an advantage gained through direct ownership of
production in another country rather than producing through a partnership
arrangement in the foreign country, such as licensing, contract manufacturing, or a
joint venture. In the presence of all three of these advantages, firms are likely to invest
in foreign production options such as offshoring.
Extending the theory to include observable factors, Dunning (1998; 2000)
developed four sub-paradigms of these advantages. They are:
1) Resource seeking (RS): to gain access to natural resources, such as agricultural
products, unskilled or skilled labor, unique technology; supply oriented;
2) Market seeking (MS): to satisfy growing or existing demand in a particular
foreign market(s);
3) Efficiency seeking (ES): to promote a more efficient division of labor or
specialization of an existing portfolio of foreign and domestic assets; related to
RS and MS; and
4) Strategic asset seeking (SAS): to protect or augment the existing ownership
specific advantages of the investing firms or to reduce those of the competitors.
Studies by Ellram et al. (2013) and Ancarani et al. (2015) use these sub-paradigms
of the OLI framework to conceptually categorize reshoring drivers discovered to that
point. These studies explain that reshoring occurs as a consequence of the changes in
the advantages in the OLI framework (Ellram, 2013; Johansson and Olhager, 2018)
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since reshoring requires consideration of internationalization factors (Presley et al.,
2016). Thus, firms decide to withdraw due to the relative decrease in ownership,
location, and internalization advantages and the four sub-paradigms that explain
specific motivations. Ancarani et al. (2015) find an association between the duration
of offshored firms and reshoring motivations, such as technology, customization,
decrease in cost differentials, physical distance, organization archetypes, firm size, and
“made-in” effect. In the same vein, looking at reshoring as a fundamentally strategic
location decision, this study uses the four sub-paradigms of location advantage as the
theoretical framework to conceptualize and empirically test a reshoring model.

Systematic literature review (SLR)
A systematic literature review (SLR) (Tranfield et al., 2003; Durach et al.,
2017) is used as a structured approach to identify a gap in the reshoring literature and
identify reshoring drivers in the extant literature. The review process follows three
major stages promoted by Tranfield et al. (2003), and six detailed steps suggested by
Durach et al. (2017). The three stages include Stage I planning the review, Stage II
conducting the review, and Stage III reporting and dissemination of the results.

Stage I – Review protocol
In Stage I, a review protocol is developed based on the research questions to guide
how the review should be conducted in Stage II. Due to the exploratory nature of the
topic, the reshoring concept is also characterized by other terms, such as back-shoring,
back-reshoring, and on-shoring. Thus, search keywords such as “reshoring”, “back-
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shoring”, “on-shoring”, and “manufacturing relocation” were used for an initial search
of the articles using ABI/INFORM and Google Scholar as the primary and secondary
database. While ABI/INFORM identifies articles focusing on business, Google
Scholar provides a wider range of scholarly resources that may be missing in the ABI
search (Howland et al., 2009). Because of the small number of studies on reshoring,
the initial search included all of the relevant sources, such as white papers, conference
proceedings, dissertations/theses, books, and journal articles published between 2009
and 2018. Reviewing references of these sources allowed for a thorough search
process. After a review, only scholarly journal articles were included in the data
synthesis and analysis to improve the rigor of the study (Gunasekaran and Ngai, 2005).
The review excluded articles that are merely anecdotal opinions without scientific
evidence. Scholarly articles were chosen based on two major inclusion criteria:
•

Articles that have a primary focus on reshoring drivers and/or motivations, or
that discuss at least one reshoring motivation; and

•

Articles that are published in scholarly journals.

The reviewed articles are not limited to a certain list of selected journals. They include
journals in operations, supply chain management, and technology with various
methodological emphases and topics.
As systematic coding and analysis are important in SLR, this study uses a
canonical coding approach promoted by Carnevalli and Miguel (2008). Detailed
coding schemes in Appendix A represent a quality evaluation of the articles based on
research objectives, which includes:
1) publication year,
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2) name of journal,
3) methodology,
4) research type,
5) definition of reshoring,
6) research context – country and industry,
7) how reshoring is initiated: reverse of a previous offshoring failure, strategic
choice, or reaction to changes in business environment,
8) research theme,
9) unit of analysis,
10) documentation type, and
11) motivations of reshoring.

Stage II – Review
As a result of the initial search and article selection process, 52 scholarly
articles in 28 different journal outlets are identified. These articles are coded based on
the name of the journal in Appendix B. Data is extracted with a primary focus on
reshoring drivers that are formed into a conceptual model. Evaluation of data quality is
conducted based on the review protocol in Stage I. The results are further explained in
the next section, Stage III.

Stage III – Report and dissemination
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Fifty-two studies published from 2009 to 2018 are identified for data analysis.
Most of the articles use conceptual and empirical methods, such as literature reviews,
surveys, and case studies that discuss at least one reshoring motivation.
Existing studies empirically examine the motivations for reshoring decisions
mainly in Europe (i.e. Germany, Finland, Sweden, and Denmark) and the U.S. Studies
suggest that reshoring decisions can differ by context due to various characteristics,
such as firm size, industry, product customization, and ownership mode (Benstead et
al., 2017; Ancarani et al., 2015). Industry can be a particularly important factor in
relocation decisions (Pennings and Sleuwaegan, 2000; Kinkel, 2012; Fratocchi et al.,
2014) because of the relation to the initial motivation of offshored manufacturing
activities.
As the extant literature suggests, initial offshoring activities are primarily
driven by low cost advantage. Both labor-intensive and technology-intensive
manufacturing are initially offshored based on resource and market seeking
motivations. However, labor-intensive manufacturing is focused on low labor costs
while technology-intensive manufacturing seeks to locate overseas to acquire unique
technology or knowledge. In the same vein, industry is prone to specific reshoring
motivations having a significant impact on “reshoring propensity” as suggested by
Canham and Hamilton (2013). The product type as well as industry are important in
that production requiring high levels of direct labor is likely to migrate to low cost
regions, not the final market which the products serve (MacCormack et al., 1994).
Furthermore, products with higher levels of customization have higher manufacturing
complexity due to limited ability to control outsourced manufacturers (Hartman et al.,
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2017). Offshoring strategy is still common for these products such as electronics and
automotive (Ciravegna et al., 2013; Mudambi and Venzin, 2010). Offshoring these
products often results in longer lead times since they require close coordination and
interaction among suppliers, especially those with a high degree of customization
(Ancarani et al., 2015).
Canham and Hamilton (2013) find that context has a significant impact on
reshoring decisions. The context derived from current research is limited because it
focuses on a certain labor-intensive industry or a “one-size-fits-all” approach versus a
high-tech, high-skilled, or highly-regulated industry. The existing reshoring
frameworks are developed to be used industry-wide. A few studies (Canham and
Hamilton, 2013; Johansson and Olhager, 2018) examine how firm-level characteristics
such as manufacturing process, export intensity, research and development (R&D)
intensity, production complexity, product specialization, production volume, and labor
intensity affect offshoring decisions. However, there has been no study which
evaluates reshoring decision factors at the industry level, which has been shown to be
important in offshoring. More specifically, this study finds no research on reshoring
conducted in the context of the healthcare-related manufacturing industry that
differentiates it from reshoring decisions in other industries.
Among 52 studies on reshoring published from 2009 to 2018, nine studies
(Kinkel and Maloca, 2009; Kinkel, 2012; Tate et al., 2014; Fratocchi et al., 2016; Zhai
et al., 2016; Delis et al., 2017; Kim et al., 2017; Heikkila et al., 2018; Johansson et al.,
2018) investigate motivations for reshoring including cases in the medical,
pharmaceutical, biotech, or biomedical industry sectors. None of these studies
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examine how their reshoring motivations may differ from other industry sectors.
Studies that examine reshoring in a standalone industry focus on metal and electrical
(Kinkel, 2014; Brennan et al., 2015), shoes and apparel (Mezzadri, 2014; MartinezMora and Merino, 2014; Baraldi et al., 2018), and electronics and automotive
(Ancarani et al., 2015). Detailed classification of the articles in the literature review is
presented in Appendix B. Appendix C describes the industry sectors that are addressed
in the reviewed articles based on the International Standard Industrial Classification of
All Economic Activities (ISIC) code.
Appendix D summarizes the reshoring drivers identified in the literature
review. In total, 122 concepts and topics are found to impact reshoring decisions based
on the search criteria. Column three in Appendix D provides the references. The result
show that factors in reshoring manufacturing tend to be dominated by variables such
as location advantages for labor costs, lower risks, and the economic health and size of
local economies (Lampel and Giachetti, 2013). Given offshoring is an antecedent for
reshoring, reshoring is often understood as simply an extension of strategic offshoring
decisions (Delis et al., 2017). This suggests that reshoring is viewed as the reverse of
offshoring. Thus, drivers for reshoring can be barriers for offshoring, and thus
challenges for reshoring can be motivations for offshoring (Wiesmann et al., 2017). In
other words, reshoring can be influenced by the original motivation for offshoring. For
example, the expected benefits of reshoring can be affected by performance and
consumers, e.g. quality issues and “made-in” effect (Ancarani et al., 2015).
The original 122 different offshoring and reshoring drivers shown in Appendix
D are evaluated for commonality and simple semantic differences. This allowed the
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drivers to be categorized into 63 items using content analysis (Seuring and Gold,
2012). The content analysis is based on understanding the variables that lead to
location decisions as suggested by Dunning (1998), which form the conceptual model
shown in Figure 2. Reshoring drivers under efficiency seeking (ES) advantage are
conceptually categorized into two factors, cost drivers and performance measures. The
content analysis revealed that many described the same underlying phenomena, but
used different terms or different theoretical frameworks without changing the meaning.
These include both internal and external factors such as labor costs, quality,
government policy, and host country risks (Kinkel and Maloca, 2009; Vanchan et al.,
2018; Heikkila et al., 2018).
Reshoring is also discussed from the perspective of supply chain flexibility and
resilience, which benefits supplier relationships through better integration (Bailey and
De Propris, 2014). From the perspective of supply chain risk, offshoring decisions are
related to product, partner, and environmental characteristics (Schoenherr et al., 2008).
Studies such as Mihalache and Mihalache (2016) and Di Mauro et al. (2018) identify
product cost as the most important risk factor to consider in offshoring decisions. They
find that over the past decade, offshoring is dominated by ES advantages, particularly
labor cost, followed by resource seeking advantages (RS), such as labor capability and
process knowledge that are too costly to obtain otherwise. This has led low cost
countries to engage in aggressive promotion campaigns to attract offshore
manufacturing (Aspelund and Butsko, 2010). In addition to financial concerns for
offshoring in developing countries, studies also find that competitive advantages, such
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as product and process innovation (Lewin et al., 2009) are important ES motivations
for offshoring decisions.
Although less dominant, motivations for strategic asset-seeking (SAS) and
market-seeking (MS) advantages are also important including proximity to customer
demand (Kinkel, 2012; Ellram et al., 2013), new product development technologies
(Mohiuddin and Su, 2013), access to local markets, government and regulation
incentives, quality of human capital, and access to talents (Caniato et al., 2015; Kinkel
and Maloca, 2009; Vanchan et al., 2018; Heikkila et al., 2018). Roza et al. (2011)
argue that firm size may create unique strategic objectives for offshoring decisions,
suggesting that strategies of small firms differ from those of large corporations. For
example, offshoring decisions for small and large firms may be driven by cost factors,
while medium-sized firms tend to use offshoring for entrepreneurial drivers that can
differentiate the firms in the competitive market by, for example, gaining access to
new markets.
MacCormack et al. (1994) point out that current cost-based models for
international manufacturing location decisions are not sustainable because firms
experience dynamic changes in their external environment. ES advantages that are
purely cost-driven can vanish quickly based on external changes. With increasing
automation and enabling technologies such as 3D printing, direct labor costs are less
emphasized in modern production processes. With less cost pressure, manufacturing
can move to locations with more SAS advantages. These factors are based on longterm perspectives such as; 1) high-value activities, 2) availability of tangible and
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intangible resources in offshored regions, and 3) recovery from offshoring failures and
changing market situations.

Importance of healthcare-related manufacturing
Recent government regulation has ratcheted up the pressure on domestic
production by U.S. medical device and drug manufacturers with concerns about
soaring drug prices (Rockoff, 2017). As the global healthcare market is rapidly
growing and expected to reach $10.059 trillion by 2022 (Deloitte, 2019), concerns
deepen. Healthcare products play an important role in this sense due to their revenue
generating effect on the economy and direct impact on human well-being.

Table 1. Definitions of medical device and drug (U.S. FDA, 2017; 2019)
Medical device
“...an instrument, apparatus, implement,
machine, contrivance, implant, in vitro
reagent, or other similar or related
article, including a component part, or
accessory which is: recognized in the
official National Formulary, or the
United States Pharmacopoeia, or any
supplement to them, intended for use in
the diagnosis of disease or other
conditions, or in the cure, mitigation,
treatment, or prevention of disease, in
man or other animals, or intended to
affect the structure or any function of
the body of man or other animals, and
which does not achieve any of its
primary intended purposes through
chemical action within or on the body of
man or other animals and which is not
dependent upon being metabolized for
the achievement of any of its primary
intended purposes.”

Pharmaceutical (Drug)
•
•
•
•

•
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“A substance recognized by an
official pharmacopoeia or formulary.
A substance intended for use in the
diagnosis, cure, mitigation, treatment,
or prevention of disease.
A substance (other than food)
intended to affect the structure or any
function of the body.
A substance intended for use as a
component of a medicine but not a
device or a component, part or
accessory of a device.
Biological products are included
within this definition and are
generally covered by the same laws
and regulations, but differences exist
regarding their manufacturing
processes (chemical process versus
biological process.)”

The two dominant product categories in this industry are medical devices and
pharmaceuticals. As defined by the U.S. Food and Drug Administration (FDA) in
Table 1, these products directly support healthcare services, and thus, patient care.
Medical devices and pharmaceuticals are examined in this study because of
their huge impact on the economy and human life. Unlike other high-tech products
such as consumer electronics, perceived risks of medical devices and drugs on human
bodies are relatively high. Medical device and pharmaceutical companies operate in
different sectors, and specific regulatory frameworks applied on each differ depending
on the level of risks (i.e. less strict on medical devices). However, both of these two
industry sectors are required to meet regulations in the product development and
manufacturing process under FDA control (in the U.S.) due to direct and indirect
impacts on humans. Additional quality system standards such as ISO 13485 and Good
Manufacturing Practice (GMP) are demanded by customers in order to meet their high
quality expectations. High levels of R&D investment are also associated with
manufacturing medical devices and drugs (Marucheck et al., 2011).
In previous years, the production and associated supply chains of medical
device and pharmaceutical manufacturers have increasingly globalized due to low cost
and favorable regulations in overseas locations such as China (Ni et al., 2017). Rising
R&D costs and the demand for low cost healthcare encourage firms to move to
emerging economies to reduce costs (Mohiuddin et al., 2017). Hamdouch and He
(2009) find that offshoring strategies of medical products significantly lower R&D
costs through the cost differential between home country and developing regions, such
as India and China. However, healthcare manufacturers experience challenges created
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by their offshoring strategy – for example, product quality risk created by a loss of
control (Gray et al., 2011). The outsourcing of R&D and technology intensive
processes, such as pharmaceuticals, can result in a higher level of defective products.
Offshoring creates longer and more complex supply chains with current
manufacturing processes regulated by manufacturing guidelines to assure safety and
quality (Chowdary and George, 2012).
Furthermore, quality risk that impacts safety is higher for these products
because there is a lag between development, production, and customer use. The issues
are often not realized until consumers are actually harmed while using the devices or
drugs. A study by Huq et al. (2016) reports that quality defects remain a major concern
in the pharmaceutical industry and that the low cost of suppliers may not compensate
for quality risk. Moser and Montalbano (2018) assert that the number of recall notices
for Chinese made consumer goods are substantially growing, showing a six times
higher recall rate than U.S. made products. Thus, these industries require higher levels
of regulatory restrictions and oversight by the FDA due to their medical use
(Marucheck et al., 2011). These issues occur due to previous offshoring strategies.
However, as Grackin (2008) argues, solely cost-based sourcing decisions are not
appropriate for manufacturing these products. These industry sectors create
competitive advantage through R&D rather than low skilled and low cost labor that is
traditionally employed in manufacturing sectors (Silva, 2008).
The issues of the current offshoring practices raise the importance of
examining reshoring in the context of healthcare manufacturing. Medical devices and
pharmaceutical industries have gained increasing importance due to distinct
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characteristics of high cost and heavily regulated production requirements. Reshoring
is increasing among medical device manufacturers due to concerns about quality,
intellectual property, etc., according to the Reshoring Initiative, an organization that is
dedicated to encouraging reshoring back to the U.S. Despite the high stakes in medical
devices and drug manufacturing, research on how these reshoring decisions are made
is sparse. However, understanding reshoring in the context of the healthcare industry
is critical because of increasing concerns about rising costs of healthcare in many
countries that affect the sustainability of businesses and social benefits.

Summary of the literature review
A company’s initial production location decision to offshore manufacturing
can influence their decision to reshore beyond the loss of expected cost advantages.
The literature describes a number of other expected benefits including, a) a greater
proximity to international suppliers and consumers, b) foreign incentives, and c) less
government regulations in developing economies. These initiatives support all four
MR, RS, ES, and SAS advantages. However, as the business and political
environments change, the expected benefits based on the original offshoring
motivations are reevaluated, leading companies to return production to their home
country. This study refers to this reevaluation and repositioning of manufacturing
decisions to meet company objectives as “right-shoring”, which includes either
offshoring or reshoring, and the right balance of domestic and foreign production.
From the perspective of sustainability, a company’s objectives must include
economic, social and environmental performance to be sustainable. In deference to the
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majority of literature measuring social performance as charity or CSR, this study
demonstrates that the impact of companies in the healthcare industry can be positive to
the economy as well as society. Benefits occur through both direct and indirect
influence on various stakeholders in society who support healthcare to individuals,
positive corporate profits, and national economic growth. In this sense, reshoring as a
right-shoring decision in recent years allows firms to consider a broader set of
variables to achieve company objectives, and thus strengthen corporate sustainability.
The medical device and pharmaceutical industries have positive impacts on
economic and social performance due to the importance of the healthcare industry that
typically pays high salaries while improving human lives. Investment in the foreign
manufacturing of these products, i.e. offshoring, is dominated by practices focusing on
cost efficiency. However, over time other important factors appear to be harmed by
this strategy, or the expected offsets for labor cost are no longer realized that relate to
market, other resources, and strategic assets. This suggests that motivations to reshore
may differ from the original objectives of offshoring. This causes firms to reevaluate
the existing investments to achieve right-shoring. They are willing to consider partial
or full reshoring to achieve the optimal balance between domestic and foreign
manufacturing. The OLI framework can explain the conceptual use of right-shoring as
a decision tool both at an empirical and analytical level. Figure 2 below is a
conceptual model developed based on the findings from the literature review. The
conceptual model categorizes reshoring drivers based on the four factors of location
advantages.
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Figure 2. Conceptual model from the literature
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SEMI-STRUCTURED INTERVIEWS
Methodology
The semi-structured interview approach used in this study is recommended
when the research is still somewhat exploratory and under-researched (Rowley, 2012),
as in the case of reshoring decisions in healthcare. A theoretical foundation can
provide structure to properly guide interview questions, but the range of possible
answers in exploratory studies are not well defined. Twelve interviews were
conducted in this study, which exceeds the recommended minimum of eight
respondents, allowing for a thorough qualitative analysis (McCracken, 1988). The
thoroughness of this type of research is often described as theoretical saturation
(Robinson, 2014) when no new information is discovered.
An interview protocol is developed with questions based on the literature
review and research objectives in line with recommendations by Walker et al. (2008)
and Kvale and Brinkmann (2009). The procedure for the interview protocol
development follows Jacob and Furgerson (2012). The interview questions are piloted
on a professor and a Ph.D. student in the area of operations and supply chain
management after an iterative review process by the authors. The interview questions
obtain information on:
1) demographics of the interviewees and their organizations,
2) role of quality, regulation, and technology in medical device and drug
manufacturing,
3) factors considered in location decisions for healthcare manufacturing, and
4) how these factors influence reshoring decisions.
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The interviews are conducted face-to-face and last approximately 30 minutes.
The interview log is recorded in writing and verified throughout the interview process
by follow-up questions with the participants. If insufficient information was collected
due to the interview setting, a follow up phone call or in person meeting was
conducted for clarification. Nine interviews were conducted at a 2018 annual meeting
of a medical device manufacturing association which included executives and
managers. The selected interviewees represent a convenience sample from the
participants who have expertise in the industry. They include mid to upper level
management, i.e. senior managers, directors, and CEOs. The interviewees are
knowledgeable in global sourcing and issues in manufacturing healthcare products due
to their experience with relevant global companies as well as focal firms and suppliers.
The organizations represented by the participants have manufacturing facilities located
in the U.S. and/or overseas (e.g. India, China, Ireland, Sweden, etc.). Three additional
interviews were conducted outside of the conference on two employees in
pharmaceutical companies and one in medical device manufacturing, both of which
are members of large size firms that serve global markets. Descriptive information on
the interviewees and their organizations is provided in Table 2.
To avoid misinterpretation and maintain consistency in using the proper
terminology in this research context, reshoring is defined to the interviewees as
“moving manufacturing back to the country of its parent company” (Ellram, 2013, p.3).
While not all twelve organizations have reshored their production, they periodically
evaluate their domestic and/or foreign manufacturing decisions to ensure that their
location strategies are still appropriate.
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Table 2. Descriptive information of interviewees and organizations
No.*

Position

Primary products/ services

A

Director of
Sales

Medical components
(tubes, etc.)

B
C

D

E

F
G
H

I

J

K

L

Company background
Distributor of medical components

Consulting process and quality improvement
Principal
Consulting
of medical device, pharmaceuticals and other
regulated manufacturing industries
Director of
Silicone based surgical
Supplier without R&D;
sales
products
Labor is the highest expense
Labor expense largest in the total expense,
Medical components,
Territory
serve global market and many global
drugs, accessories/
manager
manufacturing locations, Sweden for
supplies
prototyping
Senior
R&D and manufacturing facilities in India
Designing, developing and
business
and serving both India and U.S. market
manufacturing MedTech
development
devices (diagnostics, etc.)
manager
Business
Contract manufacturer, serve 70% U.S.
development
Medical tubing
market and different countries (Malaysia,
manager
Ireland – specialization), automated
Small business, labor intensive (manual jobs),
CEO
Dental supplies
products only manufactured in the U.S.
Operate only in the U.S.; provide sterilization
CEO
Medical device sterilizer
to medical device manufacturers
Blood management,
Global headquarter located in the U.S., a
Executive
medical products,
subsidiary of a Japanese multinational firm
vice
pharmaceuticals, medical
president
devices, cardiovascular
systems, etc.
Medical supplies for non- Emphasis on automated manufacturing and
Senior
implantable devices
mass production
advanced
(surgical products,
quality
syringes, needles,
engineer
sterilization solutions)
Global (Ireland, U.S., China, Brazil, Russia,
Medicine
Over the counter and
Japan, etc.); made and sold at manufacturing
team lead
prescription drugs
locations
Supply
Global consumers, clinical trials, global (40%
chain
Over the counter and
us, 40% EU, others)
planning
prescription drugs
team lead

No*: Each alphabet indicates different interviewees from different organizations.
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Thus, questions particularly relevant to reshoring decisions are based on their
propensity to reshore.
Among the interviewees, five of them are not directly involved in organization
that manufacture medical devices. Their organizations provide service (i.e. sales and
distribution) associated with medical devices. However, as CEOs and directors that are
rather high level decision makers in the relevant industry and members of a medical
device manufacturing and outsourcing organization, they have a solid understanding
of manufacturing processes, issues, and relevant decisions in the medical device
industry through their experience with partners in the supply chain.

Result and discussion
The results of the twelve interviews reveal important considerations for
healthcare manufacturing in terms of reshoring decisions. The results find two
variables that were not found in the literature review. They also emphasize variables
that are identified as issues of current offshoring strategy in the healthcare
manufacturing industry – quality and R&D. The findings from the interviews are
described in the following section and a summary of the individual interview results is
reported in Appendix F. The results are linked to the four factors of the theoretical
framework – RS, MS, ES and SAS.

Quality and regulation
Quality is emphasized as an important factor in manufacturing processes in the
healthcare industry. Companies in the medical device and pharmaceutical industries
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particularly strive to achieve high quality of their products and deal with continuing
safety issues due to their clinical impact on individuals.
Though achieving high quality in medical products is important, concerns
about quality issues play a major role in location decisions only if product failures or
defects occur. This is because foreign plants must go through a qualification process
prior to being selected as a possible offshoring site. However, the repeated inability of
a plant to solve its quality issues could result in reshoring. Only one interviewee
responded, “location matters to quality achievement”. For example, quality issues are
more likely to occur due to turnover in line-workers or inspectors rather than specific
location traits. This is the case with regulatory requirements as well. Quality and
regulation issues are closely related because firms are subject to government
regulations and industry practices that require compliance with quality system
standards. According to the World Health Organization (WHO) (2003), regulations for
quality systems assure that the essential quality requirements are met. Conformity to
the standards is verified through direct testing and certification. If a company serves
international markets, it must meet these standards as well as local requirements. The
Original Equipment Manufacturers (OEMs), suppliers, and contract manufacturers all
follow these standards because the government and customers expect them to provide
evidence of the product quality, and in some cases supplier selection guidelines. An
FDA approval of relevant products as well as a manufacturer is difficult, so regulatory
satisfaction is also considered an indicator of high quality. While these factors are
important in production due to potential safety issues, they do not necessarily affect
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their location decisions. Since the literature discusses quality and regulation as
decision factors, they are included in the model.

Product specialization and customer requirements
Location decisions for medical device manufacturers are heavily influenced by
product specialization. For example, some interviewees explained when production
involves a high level of customization and specialization, or R&D capabilities,
companies tend to maintain their manufacturing in home or high-tech locations (e.g.
U.S., Sweden, Ireland, etc.). For example, among the interviewees, a senior manager
from Company E with 26 different manufacturing and service locations said that the
company has its R&D prototyping offshored to Sweden. The company also produces a
wide range of products for global markets and its manufacturing locations are chosen
depending on where they can find suppliers and contract manufacturers that are
willing and able to manufacture what customers want. For the products whose
manufacturing requirements do not exist in preferred locations, companies must locate
based on the availability of resources needed for production. For example, Company
G in the U.S. is a contract manufacturer and has manufacturing facilities located in
Ireland. Despite Ireland being a costly place for manufacturing and far from the
company’s home country, products that are needed by its European customers can be
developed and made in Ireland. Compared to typical consumer goods and other hightech products, manufacturing medical devices and pharmaceutical products is highly
customer driven, due to the effects on human health and relatively short shelf life.
Thus, firms tend to have fewer options for favorable locations due to the limited
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availability of manufacturers that specialize in those products. Thus, this implies that
reshoring can be more attractive to the medical device and pharmaceutical companies
if the home location has suppliers that have capacity and capability for products in
their specialization. Customer requirements and markets are viewed as a MS factor,
while locations that have high-skilled labor to produce customized and specialized
products are viewed as a RS advantage.

Cost and risks
Cost is still an important factor for location decisions in both manufacturing
and R&D, which explains the intense competition in the medical device markets.
Offshoring can increase risk since less control typically occurs in the product
development and manufacturing process. This explains how the interviewees
described the higher likelihood of product failures and product testing costs. Thus, a
large investment in offshoring R&D and increasing manufacturing costs impacts
location decisions. To reduce product development and testing costs, firms seek low
cost regions. For example, Company E designs and manufactures medical devices.
The company manufactures in India which serves the local customers as well as the
U.S. market. It is able to reduce costs by also offshoring R&D to India. However,
while costs are lower, the quality of R&D is impacted. If reshored to the U.S., the
resulting increase in R&D costs is one of the variables in their relocation decision.
Seeking lower manufacturing and R&D costs is an ES factor, while countries that
demonstrate lower risk can be considered a SAS advantage.
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Product complexity and standardization
Interviewees uniformly mentioned that the impact of reshoring can depend on
the type of products. Medical products can be as simple as generic tubes but can be as
complicated as diagnostic devices. Thus, complexity can involve customization in
manufacturing processes that impact location decisions. Healthcare companies
represented in the interviews manufacture a wide range of products, with a small to
large product volume, serving global customers. Their materials, manufacturing
processes, the number of off-shored production and suppliers are highly variable.
Products (especially components, parts, etc.) with low product complexity such as
simple tubing or silicone bags are still manufactured in low labor cost regions.
However, production processes that are highly automated for mass production
can be made in high labor cost regions. However, not all of the participants had highly
standardized products that can be automated. They produce a variety of products,
some of which have a high degree of complexity and technological requirements that
necessitate significant involvement of skilled labor. Low complexity, highly
standardized products can be made in countries that provide ES advantages. Highly
complex products requiring more skilled labor or high tech automation are likely in
countries that can provide resource and supply oriented advantages.

Opportunities and challenges of reshoring decisions
The interviewees responded that reshoring could benefit their firms by
providing proximity to customers in their home country (MS), which subsequently
reduces lead time and transportation costs (ES). Because they recognize that the U.S.
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has the largest healthcare market in the world, U.S. based medical manufacturing
companies can benefit from locating closer to market. This allows firms to shorten
their lengthy supply chain process and logistics costs. The respondent from Company
D particularly addressed that locating the manufacturing facilities to a home location
would provide better control for the company. If issues occur in the manufacturing
process, a prompt response would be possible. Furthermore, according to the manager
from Company E which manufactures their products in India, customers tend to have
positive perceptions about “Made-In- USA” products, but only one manager
mentioned this as a factor in reshoring. Also, access to a skilled workforce is
recognized as a RS opportunity.
Reshoring can be beneficial in regard to tariffs for SAS opportunities. One of
the interviewees mentioned that through their experience manufacturing in China,
changes in government policies affected tariffs imposed on their products, as they are
currently experiencing the 2019 trade war between the U.S. and China. If reshored,
firms can take advantage of favorable policies and stability in regulations. However,
challenges of reshoring include high market competition and costs that can be higher
than offshored regions. Especially for a firm that has offshored not only manufacturing
but also the R&D process, there is a concern about increased R&D costs when
reshored.

Summary
While the interviewees find a number of benefits and opportunities which can
motivate them to move their manufacturing back home, none of the interviewed firms
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have reshored recently. However, if issues such as poor quality occurs from their
suppliers and contract manufacturers, they will make an effort to improve these issues
or look for alternative suppliers in the current market. While they are able to still
leverage manufacturing in low cost countries, the lengthy supply chain can result in
long lead times. Reshoring is one way to shorten lead time. However, most of the
interviewees indicate that they serve local customers in the offshored regions in
addition to the U.S. market. In current strategies that are targeting international
customers, the benefits of proximity to market from a supply chain perspective do not
necessarily justify reshoring. Rather, these firms ensure that customers are aware of
the longer lead times. As demonstrated in the literature, the initial decisions to
offshore were driven by low labor costs in developing countries. This was also evident
in the interviews since direct labor costs still make up the largest portion of total costs.
While reducing costs in manufacturing is important to these firms, they did not see it
as a consistent, dominating criteria that alone determines location decisions.
In addition, pharmaceutical manufacturers suggested that existing or growing
demand in local market, an MS advantage, is a strong motivation for the drugs that
have to be manufactured where they are sold. The two interviewees from major
pharmaceutical companies are a small number compared to the number of
interviewees from medical device manufacturers. However, the potential differences
in these two industry sectors need further exploration.
With heavy competition, MS advantages (i.e. the first to introduce a new
product to the market) are important in selling medical devices and pharmaceuticals.
In that sense, locating where firms can produce their specialized products can be key
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to firm performance, which has a greater effect on location decisions. These results
suggest that current offshored firms in the medical device and pharmaceutical industry
sectors are more likely to consider reshoring as a SAS decision when the original
motivation for offshoring no longer exists. New emerging opportunities do not carry
the same weight in decision-making as maintaining initial expectations. For example,
they may reshore only if they can no longer satisfy customer-driven requirements in
the offshored locations.
Lastly, the result of the semi-structured interview implies potential difference
in emphasis on decision variables between the two industry sectors. A larger number
of the interviewees represent medical device manufacturing decisions, which are based
on cost and quality factors. As one interviewee from the pharmaceutical industry
suggests, however, “demand in the local market is a critical factor relevant to the
supply chain decision process”. This may be further investigated through the survey.

Conceptual model
The results of the interviews are incorporated in the conceptual model from the
literature review. Based on the interview results, a conceptual model is reviewed and
revised as shown in Figure 3. Figure 3 shows 65 variables measuring four factors, RS,
MS, ES, and SAS. The revised conceptual model includes two additional variables,
product specialization and regulatory requirement which is differentiated regulations
related to tax benefits and tariffs.
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Figure 3. Refined conceptual model
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SURVEY
Methodology
Research design
A survey was developed, pre-tested, pilot-tested, and administered to
respondents following Dillman’s four step method (2009; 2014). The survey was
developed based on the research question, the results of the literature review and semistructured interviews, and reshoring-related studies that used a survey instrument (i.e.
Johansson et al., 2018). The initial questionnaire was tested for readability, clarity,
face validity, and content validity with a group of faculty and Ph.D. students in
operations and supply chain management that have experience with empirical methods.
After making several recommended changes, the survey instrument was pre-tested on
the group of academics again and on 18 business practitioners in an MBA program
(Pre-test 1). After the survey was refined, the second pre-test was conducted on a
group of 14 mid-level managers in the pharmaceutical industry in the presence of the
authors (Pre-test 2). During a group debriefing assessment (Ruel et al., 2016), the
managers brought up some issues with respect to the number of questions and
redundancy of the measurement items. A set of questions on reshoring indicators in
particular was comprised of 65 items, which caused concerns about low response rate
and overlaps in measurement among the items. Thus, a re-classification through a Q
sort was recommended and performed with these 14 managers, and then with 17 new
managers in the medical device industry using a Delphi approach, which reduced the
reshoring indicators to 35 items. The first round of Q sort reduced 65 items to 54 items;
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the second round of Delphi study reduced these to 35 items by seeking consensus
based on 75% threshold (McKnight, 2008).
The revised instrument was piloted on a group of 16 employees from the
medical device industry and 14 employees from the pharmaceutical industry (Pilottest). The pilot-test group recommended only minor amendments in the survey
instruction on the first page. However, there was no substantial change in the
questions. The responses from the pilot-test are compared with the final survey
responses for consistency and reliability (Armstrong and Overton, 1977). The final
questionnaire consists of a total of 14 questions asking background and demographics
of the survey respondents and their organizations, and 35 items of reshoring factors
which form 13 variables. Questions on reshoring factors ask to what degree
respondents agree with each statement using a 5-point Likert scale. The final survey
instrument is provided in Appendix G.

Reevaluation of the proposed model
This section explains the Q sort used after Pre-test 2 as a classification method
(McKnight, 2008) to refine survey items in the model. This process enables a reevaluation of identified reshoring indicators in the proposed model and an
identification of potential correlations among them. Two rounds of Q sort were
conducted in this process. The first Q sort was conducted with practicing managers of
Pre-test 2 group in the pharmaceutical industry using a Delphi approach (Brady, 2015).
The participants were asked to categorize the items into different groups based on
what each item purports to measure. Sixty-five items were classified into 15 different
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groups, and those in the 15th group “others” were re-evaluated or removed, resulting in
reduction of 65 to 54 items. The second round of Q sort was conducted to reach
consensus on the conceptual classification of the participants. It was conducted on 17
managers from medical device manufacturers. Corresponding to the threshold of 75%
consensus by McKnight (2008), items that obtained below 75% agreement were
dropped. This results in 35 items that measure different reshoring motivations. Details
on classified items through Q sort are presented in Appendix H, and a refined
measurement model based on the result is shown in Figure 4. The re-evaluation and
the refined model provide insights on how managers look at the variables in the
decision making process. Because of their suggested relationships, first order and
second order factors are supported in the measurement model. Each measurement item
for the 13 variables and four factors is described in Appendix H with the Q sort result.
The re-evaluation also results in the change of cost-related variables to non-ES
advantages, for example, labor cost to RS advantage.
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Figure 4. The revised measurement model from Q Sort

Survey administration
The survey is delivered online using Qualtrics which is a company that supports
survey research services such as survey development, data collection (survey
administration), and data analysis. The survey administration uses two different
channels:
1) self-survey administration (participants are verified to work in relevant
organizations by the researchers)
2) survey administration through a research firm
A combination of these two channels overcomes weaknesses underlying each of these
survey administration approaches. For example, a self-administered survey is
criticized for its inability to obtain a satisfactory sample size, while a paid survey
41

through a research firm involves a risk of misrepresented qualifications or data due to
reward motives (Schoenherr et al., 2015). To improve these issues, this study employs
both approaches. Differences in the survey administration procedures of each
approach are described in Table 3.

Table 3. Description of survey administration procedures
Self-administered survey
Survey
administration
Survey platform

Research firm

Authors

Qualtrics

Qualtrics

Qualtrics

Survey method

Online

Online

Incentive

No incentive

Reward pay provided

Survey invitation

N/A

281 (survey accessed)

Responses collected

137
• Survey invitations were
sent to pre-determined
respondents.
• Qualifications of
respondents were verified
by their affiliations with
relevant organizations and
associations (e.g.
Association of U.S.
medical device
manufacturers)

105
• Qualifications based on
“managers at
Pharmaceutical/Medical
Manufacturing firms –
screened out “Individual
Contributor” or “Entry
Level”
• An email invitation is sent
to potential qualified
respondents in panel
informing research
purpose, duration,
incentive, etc. on a variety
of platforms.

Data collection
procedure

One issue that occurs with this combined survey administration approach is the
difficulty in determining a response rate since it occurs through survey research firms.
Survey invitations are sent to individuals by the authors and the survey firm only
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provides information on the number of accessed surveys, which makes it difficult to
determine a response rate.

Results and discussion
Sample analysis
A total of 242 responses were obtained. Sample demographics of the final
sample of 186 respondents by job experience, firm size, and products are presented in
Tables 4 – 8 below. Table 4 shows 74.2% of the sample companies that have reshored
all or part of manufacturing (firm level) and/or are currently considering to reshore.
Table 5 presents the levels of relevant manufacturing decisions made by the
respondents in their firms, and the number of job experience in the relevant industry.
75.8% of the respondents participate in intermediate to very high levels of
manufacturing related decision making. Table 6 shows the types of products made by
the companies and firm sizes. Approximately 98% of the companies in the sample
manufacture medical devices and/or drugs; half of these companies are large firms
with more than 1000 employees. Table 7 shows the four product characteristics such
as labor intensity, technology intensity, product standardization (customization), and
product complexity. Table 8 shows the locations of headquarters and ownership of the
sample companies. Over 85% of these firms have both ownership and headquarter
locations in the U.S. The initial sample is explained in Section 4.2.2. A majority of
participant organizations have reshoring experience or are currently considering
reshoring decisions.
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Table 4. Current reshoring experience and reshoring considerations of the sample
companies
Reshoring

Frequency

Percent

No reshoring

48

25.8

Reshored/considering reshoring

138

74.2

Total

186

100.0

Decision level

Frequency

Percent

Job Experience

Frequency

Percent

None

16

8.6

<1 year

16

8.6

Very low

10

5.4

1-5 years

38

20.4

Low

18

9.7

6-10 years

49

26.3

Intermediate

48

25.8

11-15 years

36

19.4

Very high

93

50.0

16-20 years

46

24.7

Total

185

99.5

Total

185

99.5

N/A

1

.5

N/A

1

.5

Total

186

100.0

Total

186

100.0

Table 5. Relevant work experience of the sample respondents

Table 6. Product types and firm size of the sample companies
Product types

Frequency Percent

Firm size

Frequency Percent

Medical devices only

73

39.2

0-9 employees

2

1.1

Drugs only

69

37.1

10-49 employees

12

6.5

Both medical devices and drugs
Involved in relevant decision
making (e.g. sales)
Not involved at all.

40

21.5

50-249 employees

29

15.6

2

1.1

500-999 employees

46

24.7

1

.5

1000-5000 employees

20

10.8

Total

185

99.5

5000 or more

76

40.9

N/A

1

.5

Total

185

99.5

Total

186

100.0

N/A

1

.5
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Table 7. Product characteristics of the sample companies
Product standardization Product complexity Tech intensity

Labor intensity

Scale

Freq.

Percent

Freq.

Percent

Freq.

Percent

Freq.

Percent

Very low

6

3.2

0

0

18

9.7

4

2.2

Low

18

9.7

29

15.6

25

13.4
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22.6

Moderate

45

24.2

56

30.1

53

28.5

62

33.3

High

0

0

0

0

0

0

0

0

Very high

116

62.4

100

53.8

89

47.8

77

41.4

Total

185

99.5

185

99.5

185

99.5

185

99.5

N/A

1

.5

1

.5

1

.5

1

.5

Total

186

100.0

186

100.0

186

100.0

186

100.0

Table 8. Location of headquarters and ownership of the sample companies

Locations

Headquarter

Ownership

Frequency

Percent

Frequency

Percent

Non-U.S.

19

10.2

26

14.0

U.S.

165

88.7

159

85.5

Total

184

98.9

185

99.5

N/A

2

1.1

1

.5

Total

186

100.0

100.0

186

Descriptive statistics and data cleaning
The initial sample of 242 responses is obtained through the online survey and
subjected to screening for incomplete responses and outliers. The first stage of data
screening procedure involves an identification of suspect responses that can
significantly affect data analysis. Of the 242 responses, 2 responses that recorded the
initiation of the survey but did not have answers were deleted.
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Table 9. Descriptive statistics of the final sample
Variable

Mean

Sum

Square

Deviation

Median

Range

Skewness

Kurtosis

VACSV

2.392

445

348.349

1.372

2

4

0.83

-0.453

VB1INFRA

4.328

805

212.995

1.073

5

4

-1.233

0.322

VB2TRANC

3.57

664

375.591

1.425

3

4

-0.293

-1.347

VC1RAWMA

4.274

795

247.016

1.156

5

4

-1.244

0.282

VC2PROXS

3.285

611

329.898

1.335

3

4

0.138

-1.267

VC3CONTM

4.247

790

286.624

1.245

5

4

-1.353

0.524

VD1ECONS

3.258

606

383.613

1.44

3

4

0.043

-1.391

VD2CORDC

4.339

807

261.661

1.189

5

4

-1.508

0.919

VD3PRODC

4.091

761

283.446

1.238

5

4

-0.877

-0.641

VD4IMPOR

4.253

791

279.124

1.228

5

4

-1.315

0.385

VD5INVMG

4.161

774

279.161

1.228

5

4

-1.046

-0.272

VD6FLEXI

2.962

551

312.737

1.3

3

4

0.469

-0.918

VD7PRODU

4.452

828

208.065

1.061

5

4

-1.741

1.965

VE1PRODS

3.763

699.848

363.542

1.402

5

4

-0.552

-1.114

VE2PROXC

3.22

599

423.962

1.514

3

4

0.064

-1.538

VE3MADEI

3

558

468

1.591

3

4

0.21

-1.543

VE4LEADT

4.333

806

257.333

1.179

5

4

-1.461

0.769

VF1POLIR

4.124

767

332.156

1.34

5

4

-1.132

-0.186

VF2ADMIN

3.78

703

339.962

1.356

5

4

-0.549

-1.006

VF3REGRE

4.565

849

187.726

1.007

5

4

-2.165

3.52

VF4GVTSU

4

744

328

1.332

5

4

-0.854

-0.69

VG1VOLDE

2.409

448

252.946

1.169

2

4

1.035

0.438

VG2GOVTP

3.78

703

369.962

1.414

5

4

-0.606

-1.038

VHENVT

2.699

502

277.14

1.224

2

4

0.749

-0.319

VI1LABOR

4.258

792

303.613

1.281

5

4

-1.388

0.449

VI2LABOR

3.704

689

378.737

1.431

5

4

-0.437

-1.351

VJ1CONTC

4.376

814

239.656

1.138

5

4

-1.568

1.212

VJ2DISTA

2.403

447

278.758

1.228

2

4

0.884

0.049

VJ3REORG

2.339

435

255.661

1.176

2

4

1.001

0.427

VK1IP

4.263

793

296.091

1.265

5

4

-1.356

0.332

VK2SECUR

4.317

803

278.285

1.226

5

4

-1.486

0.778

VLAUTOMA

3.624

674

375.656

1.425

3

4

-0.307

-1.45

VNQUALIT

4.468

831

222.306

1.096

5

4

-1.868

2.268
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VO1RND

2.806

521.988

355.028

1.385

2.494

4

0.509

-0.971

VO2RNDCO

2.674

497.319

376.667

1.427

2

4

0.632

-0.929

Then, 16 “straight-liners”, which “occurs when survey respondents give
identical (or nearly identical) answers to items in a battery of questions using the same
response scale” (Kim et al., 2019, P. 214), were removed in consideration of their
effect on data quality. Ten additional responses that were not qualified based on a
screener question on job level, i.e. individual contributor were dropped. Ten
disqualified responses are from participants that claimed their affiliated organizations
did not manufacture medical devices or pharmaceutical products or are not involved in
relevant decision making. This first stage eliminates 30 responses resulting in 212
responses. After deleting suspect and/or disqualified responses, a missing value
analysis is conducted for imputation. Approximately .2% of data points are missing
and these are imputed using EM imputation method in EQS as EM imputation is
considered to produce less biased estimates (Musil et al., 2002). Finally, 26 repeated
outliers, identified as an outliers more than once, are dropped.
The final sample of 186 responses are included in the analysis. Table 9
provides descriptive statistics of the final sample. Among 35 reshoring drivers,
regulatory requirements (V3REGRE) and quality (VNQUALIT) were ranked as the
top motivation for reshoring decisions, which is consistent with the findings from the
interviews.

Result and discussion
Prior to conducting confirmatory factor analysis (CFA), exploratory factor
analysis (EFA) is conducted for each factor using SPSS to seek the underlying
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structure of the measurement items (Tokman et al., 2006). The measurement items
with low correlations are dropped from the factors and the measurement model is
reconfigured. Table 10 presents the initial 35 items included in EFA.

Table 10. Initial measurement items before EFA
Reshoring drivers
Infrastructure
Availability of qualified personnel
Availability of raw material
Government subsidies
Transportation cost
Production cost
Labor cost
Import cost
Proximity to supplier
Clusters
Political risks
Government subsidies
Quality
Inventory management
Control and coordination
Administration cost
Coordination and communication cost
Lead time
Productivity
IP
Security
Reorganization
Economies of scale
Automation
Distance
R&D capability
Proximity to customers
Made-in effect
Proximity to suppliers
R&D cost
Company share value
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Factors

n/a

RS

MS

Location advantage
ES

SAS

The final measurement model includes four to eight items in each factor with
the total number of 20 measurement items in the reconfigured model. The result of the
model fit assessment of the modified model is presented in Table 11. The CFI is .94
and RMSEA is close to .082, both of which indicate a good fit. The results show a
good fit of the revised measurement model and the hypothesized relationships between
measurement items and factors. The detailed model description and coefficient
estimates of each item and variable are presented in Figure 5. The positive estimates
suggest positive relations of the variables and the items. The survey results indicate
the empirical relationship between the variables and factors that affect location
decisions. However, the contribution of R&D to the SAS is somewhat weaker than
other variables. This provides an important managerial implication because currently a
large number of medical devices and pharmaceutical companies still move to countries
such as China and India for lower R&D costs in addition to manufacturing costs.

Table 11. CFA result fit indices of the measurement model
Fit indices
Adjusted chi-square

146.47

Degrees of freedom

190

Bentler-Bonett Normed Fit Index (NFI)

0.897

Comparative fit index (CFI) – Robust

0.940

Root mean-square error of approximation (RMSEA) – Robust

0.082

Cronbach’s alpha

0.901

The relationship between R&D location and quality issues needs further
investigation. However, this may suggest that low R&D expenditure in the current
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offshore region is perceived to be a barrier that impacts economic performance related
to company share values at the risk of quality problems. The survey results for each
group, pharmaceutical companies versus medical device companies, were compared
and presented no significant differences between the groups.

Figure 5. Factor loadings of CFA result – modified CFA model
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The findings from this study provides a framework that informs decisionmakers in the medical device and pharmaceutical manufacturing industry. While the
generalizability of the decision model may be limited because of the contextual focus
of this study on manufacturing in the healthcare industry, it contributes to the literature
in two major aspects. First, this study using the four sub-paradigms of the OLI
framework contributes to the literature by empirically testing the theoretical
framework to extend the applicability of the theory to business practice. Second, this
study fills a research gap by providing an industry-specific decision framework that
incorporates differences in decision factors among various industry sectors.
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ANALYTICAL MODEL
Using the results of the interviews, several parameters are discovered that support
the development of a rudimentary analytical model with an optimal solution. While an
empirical investigation of this study finds factors such as quality and regulation as
important considerations for reshoring decision, the analytical model focuses on the
difference in the transportation cost and the resulting total cost of a location decision.
The objective function is the minimization of total costs. This model is considered
rudimentary because it is the first attempt to develop an optimal right-shoring solution
based on the available real-world data. It does not claim to be robust because there
may be other variables that can be included as more information is known. The model
complements the empirical findings by providing a cost factor, transportation cost,
which was rather less emphasized in the previous cost-based location decision. While
this rudimentary analytical model uses the variables found through the literature
review and interviews, it does not demonstrate the important factors such as quality
and regulatory issues as a cost differentiator in this model. It is because quality and
regulatory issues can vary by regions rather than being domestic or foreign.

Objective Function:
Total cost = {[Annual demand/(Order quantity/Fixed order cost)]/[Unit
cost*Transportation cost]} + [(Order quantity/2)*Transportation cost]
TC = {[D/(Q/FC)]/[C*T]} + (Q/2)*T
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Where:
d = domestic location (reshoring option)
f = foreign location (no reshoring option)
TC = total cost; where TCd is compared to TCf and the location decision is
based on the lowest total cost.
D = annual demand (forecast), is uniform across locations
C = unit cost, varies by location
FC = fixed order cost, varies by location
Q = order quantity, is not limited by location
OF = order frequency, is stated in time units and can vary by location
T = Transportation cost, is stated as a percentage of C and varies by location

The assumptions of the model are as follows:
1) Quality: Since quality in reshoring is considered essential, no location will be
considered that cannot meet minimum quality standards. Therefore, quality is
treated as a qualifier in this model and thus considered as uniform across all
possible locations. A quality variable may be represented as a factor in demand
forecasts by adding a safety stock value to the basic forecast that represents
additional production need to cover defective goods (or a defect percentage);
however, none of the interviews shared their quality records so it is not
included in this model.
2) Location (L): It is assumed that manufacturers have at least one domestic and
one foreign location option when considering reshoring.
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3) Manufacturing: It is assumed that a company controls the manufacturing
schedule regardless of the locations. This includes a company-owned process
or a contract manufacturer.
4) Customer demand (D): It is assumed that customer demand or demand forecast
is not affected by location.
5) Inventory: The interviews revealed that drugs and medical devices have short
shelf lives and thus are shipped just in time. Thus, it is assumed that holding
costs are uniform across location.
6) Service levels: Service levels are considered uniform across all locations. The
interviews revealed that regulators and customers to not tolerate out of stock
items. Companies will spend more on transportation to prevent late orders and
stock-outs.
7) Transportation cost (T): Companies will spend more on transportation to keep
service levels high. It is often expressed as a function of unit costs in
managerial accounting. Foreign locations are considered to have higher
transportation costs than domestic production due to the distance from the
market (locating to serve the local customers is not considered in the model
due to variability among manufacturers).
8) Production: All locations are considered to be available for production for 250
days per year and 24 hours per day. This accommodates the typical availability
for developed countries in Europe, Asia, and North America.
9) Fixed order cost (FC): It can vary by location.
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10) Order quantity (Q): It can vary but should be based on an optimal quantity
considering the minimization of transportation and ordering costs.

An example below demonstrates a hypothetical situation of how a firm will decide
to right-shore based on the analytical model above. It is assumed that:
1) Quality is equal, comparable labor/technology 2) At least 1 foreign and 1
domestic option
3) Contract manufacturing avoids large initial investment
4) Annual forecast does not depend on location and is stable
5) No significant inventory holding cost due to JIT
6) Service levels are equal, transportation costs are the differentiator.
7) Transportation cost can be represented as a function of C, which represents
the time differential.
8) Production days = 250 days/year, 24/5
9) Foreign location provides lower total manufacturing costs.

1) Total cost of domestic (d) production (TCd)
TCd = {[1,000,000/(20,000*5,000)]/(100*.25)}+[(20,000/2)*(100*.25)] =
250,000
Where:
Annual forecast (F) = 1,000,000 units
Unit cost (Cd) = $100/unit
Fixed cost per order (FCd) = $5,000
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Order size (Qd) =

= 20,000 units

Transportation cost (Td) = 25% of unit cost = $25
Order Frequency = 1 week, minus 2 weeks for holidays = 50 orders/year.
Orders ship every 5 days.

2) Total cost of foreign (f) production (TCf )
TCf= {[1,000,000/(7,071*1,000)]/(40*1.0)}+[(7,071/2)*(40*.1.0)] =
141,420.10
Sf=1,000, [1,000,000/(7,071*1,000)]+[(7,071/2)*(40*1)] = 141,420.14
Sf=5,000, [1,000,000/(7,071*5,000)]+[(7,071/2)*(40*1)] = 141,420.03
Sf=5,000, [1,000,000/(7,071*5,000)]+[(7,071/2)*(70.71*1)] = 249,995.23
Where:
Annual forecast (F) = 1,000,000 units
Unit cost (Cf) = $40/unit, including customs and tariffs
Fixed cost per order (FCf) = $1,000
Order size (Qf) =

= 7,071 units

Transportation cost (Tf) = 100% of unit cost = $40Order Frequency = 42 hours,
minus 2 weeks for holidays = 142 orders/year. Orders ship every other day.

3) Right shoring
TCd = TCf @ FCf= $1,000 and C = $70.71
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This example demonstrates that when the total cost per unit is below $70.71, a
manufacturer will choose to offshore production. At $70.71 or higher unit cost, a
manufacturer will choose to reshore. However, foreign production does allow for more
flexibility with smaller, more frequent ordering. This also implies that with increasing
labor cost in foreign locations and tariffs imposed upon imported products, firms may
re-evaluate their total cost analysis and location decisions.
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CONCLUSION
This study attempts to develop and empirically test the OLI framework as a
theoretical grounding that explains the expected benefits of offshoring and reshoring
in the context of the healthcare manufacturing industry. The literature review
identified a number of reshoring motivations in the extant literature and found no
research focusing on a specific industry, particularly in the context of healthcare. In
spite of the number of articles that attempted to develop an empirically tested
reshoring decision model, studies were limited to reshoring frameworks based on a
“one-size-fits-all” approach. As the global healthcare market extensively grows, the
importance of manufacturing products that support healthcare services has increased.
In that sense, this study fills the research gap in current reshoring literature by
examining reshoring motivations of the medical device and pharmaceutical industries.
A major theoretical contribution is to empirically test the theoretical framework, the
OLI, which had only been used to conceptually explain and categorize the current
motivations for location decisions as competitive advantages. The semi-structured
interviews found the importance of emphasized factors such as quality, regulatory
requirements, and product specialization on current location decisions.
The results of the survey find that quality and regulatory requirements
contribute to current and future reshoring decisions, which is consistent with the
findings from the literature and interviews. The CFA results suggest that R&D
capability has a positive but weak relationship with strategic asset advantages that can
lead to reshoring decisions. This result can be understood in a way that managers in
the medical device industry and pharmaceutical manufacturers see R&D in offshore
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regions as an opportunity as opposed to reshoring. Furthermore, this may reflect
offshoring practices in the medical device and pharmaceutical industries due to the
availability of R&D outside the home country and even at a lower cost (e.g. India).
However, this also provides important managerial implications for practicing
managers. While offshoring for lower R&D costs helps offset rising product costs,
product recalls according to the FDA continue for various quality issues including
non-sterility, cracks, leakage, identification of potential safety issues, etc., which may
potentially lead to a higher cost in the long term.
Finally, the analytical model in this study incorporates the impact of
transportation costs and the resulting total cost on estimating parameters that lead to
optimal right-shoring decisions. The example reflects the current reshoring
consideration in recent years as firms realize the impact of transportation costs on their
initial total cost analysis that focused on low labor and manufacturing cost in foreign
locations. Since the manufacturing cost started increasing in some developing
economies such as China and the issues from offshoring occurred (e.g. quality), the
importance of re-evaluating the total cost analysis has been addressed. The model is
limited in that firms are assumed to have reshoring production as the only alternative
to foreign production while in reality this may also lead to further offshoring decisions
to where the total cost estimate is lower.
The findings of this study make several practical implications. This study
simplifies the existing reshoring decision frameworks by providing an industryspecific reshoring model based on the location advantages. Business managers may
use the model to evaluate and prioritize factors involved in reshoring beyond cost
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factors. Likewise, policy makers can benefit from this study to understand the factors
that contribute to reshoring decisions and, thus, to make relevant policies to encourage
reshoring or discourage offshoring as a way to promote domestic production for
growth in the local economy. Lastly, this study contributes to sustainability by
extending the domain of social and economic sustainability to reshoring. It suggests
that social benefits can be achieved outside of the traditional charitable activities
through a firm’s location decision that can also sustain economic performance.
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LIMITATION AND FUTURE RESEARCH DIRECTION
This study makes a contribution to the literature and business practice by
suggesting an empirically tested reshoring model. However, there are several
limitations that suggest future research directions.
First, future research can increase the sample size. The number of responses
obtained in this study satisfies the recommended sample size for analysis. However, a
larger sample size can increase the effect size and improve the model fit. Related to
this, future studies may consider a survey administration approach that provides a
determinate response rate to improve statistical validity.
Another future research effort can be made in terms of the scope of the study.
Even within the same product category, the product complexity varies and
requirements in the manufacturing process for each type of product can vary. For
example, among the medical device companies, the level of product complexity varies
determining labor intensity and ability to automate manufacturing processes. This can
vary to a greater extent for larger firms that provide a wide range of product lines.
Further investigation on this matter can be done using field research or in-depth
interviews.
Also, the proposed analytical model is limited focusing on the transportation
cost and resulting total cost as the only differentiator. It is noted that quality and
regulatory requirements vary by each region rather than by manufacturing in domestic
country or foreign location. However, future studies can propose an advanced
analytical model by incorporating parameters that can differentiate quality and
regulation factors.
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Lastly, while this study stresses the need of industry or product specific
investigation on reshoring decisions, future studies can test the proposed model in
different contexts. With the criticism on the OLI framework that is considered
contextual with limited generalizability, the theoretical framework has been mostly
used for a conceptual understanding of international investment decisions (i.e. Ellram
et al., 2013; Ancarani et al., 2015). Empirical tests of factors impacting location
decision as an investment decision can help validate generalizability of the OLI
framework in international location decisions to various industry sectors.
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APPENDICES
Appendix A. Codification of the systematic literature review (SLR)
Classification codes
A
A1
A2
A3
A4
A5
A6
A7
A8
B
B1
B2
B3
B4
B5
C
C1
C2
C3
C4
C5
C6
C7
C8
C9
C10
C11
C12
C13
C14
C15
C16
C17

Research methodology
Analytical
Theoretical (Conceptual)
Literature review
Survey
Case study
Experiment
Quantitative (Statistical analysis)
Interview
Research type
Journal
Thesis
Conference proceedings
White paper
Industry paper
Journal
Operation Management Research
Journal of Business Research
Cambridge Journal of Regions, Economy and Society
Journal of World Business
International Journal of Production Economics
Journal of Manufacturing Technology Management
Journal of Purchasing & Supply Management
Journal of Operations Management
International Journal of Traffic and Transportation Engineering
Operations and Supply Chain Management
Growth and Change
Industrial Marketing Management
International Journal of Physical Distribution & Logistics Management
Journal of Engineering Manufacturing
Management
International Journal of Production Research
Supply Chain Forum: An International Journal
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C18
C19
C20
C21
C22
C23
C24
C25
C26
C27
C28
E
E1
E2
F
F1
F2
F3
F4
F5
F6
G
G1
G2
G3
H
H1
H2
H3
H4
H5
H6
H7
H8
I
I1
I2

Business Horizons
Manufacturing & Service Operations Management
International Journal of Management Cases
Journal of Textile and Apparel, Technology and Management
International Business and Global Economy
International Journal of Operations & Production Management
Journal of the Academy of Marketing Science
Competition and Change
Journal of Supply Chain Management
Strategic Outsourcing: An International Journal
European Business Review
Definition of reshoring
Home country (backshoring)
Relocation (reshoring)
Context/country
United States
Europe
Asia
Others
Single country (regional)
Multiple countries (international)
Reshoring perspective
Location decision
Sourcing decision (governance mode)
Others
Reshoring types
Backshoring for outsourcing
Backshoring for insourcing
In house backshoring
Outsourced backshoring
Non-backshoring for outsourcing
Non-backshoring for insourcing
In house non-backshoring
Outsourced non-backshoring
Research theme
Reshoring motivations/drivers
Reshoring decision framework
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I4
I5
J
J1
J2
J3
J4
J5
J6
J7
K
K1
K2
K3
K4
K5
K6
L
L1
L2
L3
L4
L5
L6
L7
L8
O
O1
O2
P
P1
P2
P3

Impact of reshoirng
Reshoring process
Impact on reshoring
Unit of analysis
Single reshoring decision/specific activity
Firm
Production
Product
Reshoring volume
Country
Individual (customer)
Documentation
Questionnaire
Interview
Document analysis
Public data
Press information (e.g. newspaper)
Bibliography
Term
Reshoring
Re-shoring
Inshoring
Nearshoring
Backshoring
Onshoring
Rightshoring
Back-reshoring
Time frame
Temporal
Longitudinal
Reshoring initiation
Correction (offshoring failure)
Reactive decisions
Strategic change
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Research type
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reshoring
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Reshoring
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insourcing)
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I3, (demand
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Unit of analysis
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Documentation
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L1

L1

L5
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analysis
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(2017)
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(2017)
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Research
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Research type
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reshoring

E1
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E1
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Context/Count
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F2, F6

F1
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G1

G1, G2
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Reshoring
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H2, H3

H2, H4

n/a

n/a

Research
theme

I1

I1, I2

I2

I3

Unit of
analysis
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J3

J4

J5

Documentation
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K2
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L1

L1, L4
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Time frame
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Reactive
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Context/Count
ry
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Reshoring
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H1, H2, H3, H4,
H5, H6, H7, H8
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H4 – Gray et al.
(2013))

H1, H2, H3, H4

Research
theme
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Unit of
analysis
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Documentation

K6
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K5, K6
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product)
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No
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Authors
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(2016)
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(2016)
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(2016)
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Research
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H5, H6, H7, H8
(nearshore –
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G1

Unit of
analysis

Reshoring
types

C17

n/a (H1, H2, H3, H2, H4, H6, H8
H4)

n/a

I1

I2

I5

J2

J1

J1

J3

Documentation

K3, K6

K4, K5, K6

K2

K2

Term

L1

L1

L2, L7

L5

Time frame

n/a

O1

O1

O2

Reshoring
initiation

Strategic
change/correctio
n
n/a

Correction

Correction
(failure)

Correction
(failure)

No

No

No

Research
theme

Healthcare
(Med device or
product)
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Mlody (2016)

Ocicka (2016)

Presley et al.
(2016)

C22

Moradlou &
Backhouse
(2016)
C14

Journal
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C17

Research
methodology

A2

A3

A4

A3, A7

Research type

B1

B1

B1

B1

Definition of
reshoring

E1

E1

E1

E1

Context/Count
ry

F2

F2 (UK)

F2 (Poland)

n/a

Reshoring
perspective

G1

G1, G2

G1, G2

G1, G2

Reshoring
types

n/a

H1, H2, H3, H4

H1, H2, H3, H4

n/a

Research
theme

I1

I1

I1, I3

I2, I4

Unit of
analysis

J6

J3

J3

J1

Documentation

K6

K6

K1

K3, K6

Term

L1

L2

L1

L1

Time frame

n/a

n/a (O1)

n/a (O1)

O1

Reshoring
initiation

Reactive
decisions &
Strategic change

Correction
(failure)

Correction
(failure)

Strategic change

Healthcare
(Med device or
product)

n/a

n/a

n/a
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Robinson &
Hsieh (2016)

Srai & Ane
(2016)

Stentoft et al.
(2016a)

Stentoft et al.
(2016b)

Journal
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C16

C1

C1

Research
methodology

A5

A3

A4, A5

A3

Research type

B1

B1

B1

B1

Definition of
reshoring

E1

E1

E1

E1

Context/Count
ry

F2 (UK)

F2 (UK, France)

F2 (Denmark)

n/a

Reshoring
perspective

G1

G1

G1, G2

G1

Reshoring
types

H1, H2, H3, H4
(H2)

n/a

H3

n/a

Research
theme

I3

I1

I1

I1

Unit of
analysis

J1

J1

J1

n/a

Documentation

K2

K6

K1, K2

K6

Term

L1

L1

L5

L5

Time frame

O2

n/a

O1

n/a

Reshoring
initiation

Correction
(failure)

Strategic change

Reactive
decisions

Reactive
decisions

Healthcare
(Med device or
product)

No

n/a

n/a
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Authors

White &
Borchers (2016)

Zhai et al.
(2016)

Ancarani et al.
(2015)

Brennan et al.
(2015)

Journal

C10

C1

C5

C23

Research
methodology

A4

A7

A7

A2

Research type

B1

B1

B1

B1

Definition of
reshoring

E1

E1

E1

E1

Context/Count
ry

n/a (F1)

F1

F2, F6

F2 (Germany)

Reshoring
perspective

G1

G1

G1, G2

G1

Reshoring
types

n/a

H1, H2, H3, H4

n/a

n/a (H2, H4)

Research
theme

I1, I2

I1, I5

I1

I1, I5

Unit of
analysis

J1

J1

J1

J1

Documentation

K1

K4, K5

K5

K6

Term

L1

L1

L1

L2, L5

Time frame

O1

O2

O2

n/a

Reshoring
initiation

Strategic change

Reactive
decisions

Correction (exit
of offshoring)

Strategic change

Healthcare
(Med device or
product)

No

No

n/a

No
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Authors

Grappi et al.
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Gylling et al.
(2015)

Arlbjorn &
Mikkelsen
(2014)
C7

Bailey & De
Propris (2014)

Journal

C24

C5

Research
methodology

A6

A5 (action
research)

Research type

B1

B1

Definition of
reshoring

E1
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Context/Count
ry

F2(Italy)

F2 (Finland)

Reshoring
perspective

G1

G1

G1

Reshoring
types

n/a, partial vs.
full reshoring

H2, H3 (inhouse)

H1, H2, H3, H4

Research
theme

I5

I2

Unit of
analysis

J7

J3

J2

Documentation

K1, K2

n/a (K2)

K5, K6

Term

L1

L5

L5

L1

Time frame

O1

O2

n/a

n/a

Reshoring
initiation

Strategic change
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driven)
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n/a
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Healthcare
(Med device or
product)
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No
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A2

B1

B1

E2

F2 (Denmark)

I1 (notes and
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Propris (2014)

Fratocchi et al.
(2014)

Kinkel (2014)
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Martinez-Mora
& Merino
(2014)
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methodology
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A4
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F2 (UK)
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F2 (Germany)
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reshoring
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I1 (notes and
debates)

H1, H2, H3, H4
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J2
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Reshoring
perspective
Reshoring
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I1

Unit of
analysis
Documentation

K2, K6

K6

K4
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L1

L8
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Time frame

n/a

O2

O1

Correction
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Reactive
decisions
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No

Reshoring
initiation

Healthcare
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product)

No
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F1
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Reshoring
perspective
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Reshoring
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J2
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reshoring
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ry

Research
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F3 (India)
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O1

O1

Strategic change

No

Reactive
decisions
(changes in the
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change

O2
(reshoring as
O1)
Correction
(failure)

Healthcare
(Med device or
product)

n/a

n/a

Yes
(medical,
precision
and optical
instruments)

Yes
(medical,
precision
and optical
instruments)

Research
theme

Editorial

77

I1

Kinkel & Maloca (2009)
Kinkel (2012)
Canham & Hamilton (2013)
Bailey & De Propris (2014a)
Bailey & De Propris (2014b)
Kinkel (2014)
Martinez-Mora & Merino (2014)
Mezzadri (2014)
Tate et al. (2014)
Ancarani et al. (2015)
Brennan et al. (2015)
Gylling et al. (2015)
Abbasi (2016)
Ashby (2016)
Foerstl et al. (2016)
Fratocchi et al. (2016)
Joubioux & Vanpouke (2016)
Ocicka (2016)
Robinson & Hsieh (2016)
Stentoft et al. (2016a)
Zhai et al. (2016)
Albertoni et al. (2017)
Brandon-Jones et al. (2017)
Chen & Hu (2017)
Delis et al. (2017)
Gray et al. (2017)
Hartman et al. (2017)
Kim et al. (2017)
Baraldi et al. (2018)
Heikkila et al. (2018)
Johansson & Olhager (2018)
Johansson et al. (2018)
Vanchan et al. (2018)

V
V

V
V

V

V
V
V

V
V

V
V

Publishing and
printing

Pulp, paper and
paper products

Wood and
wood products

Textile, textile
products,
leather and
leather
products

ISIC Code

Food products,
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Martinez-Mora & Merino (2014)
Mezzadri (2014)
Tate et al. (2014)
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Vanchan et al. (2018)

V
V

V
V

V
V

V
V

Machinery and
equipment n.e.c.
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n.e.c.; recycling

Transport
equipment

Medical, precision
and optical
instruments, etc.

Office machinery,
computers and
communication
equipment

Electrical
machinery and
apparatus n.e.c.
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V
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Heikkila et al. (2018)
Johansson & Olhager (2018)
Johansson et al. (2018)
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V
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Brennan et al. (2015)
Gylling et al. (2015)
Abbasi (2016)
Ashby (2016)
Foerstl et al. (2016)
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Johansson & Olhager (2018)
Johansson et al. (2018)
Vanchan et al. (2018)

Biomedical/
medical

ISIC Code

V

V

V

V

V
V
V
V

V

*References with no industry focus are excluded in the table.
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Appendix D. Reshoring drivers in the literature
No. Factors

Citations and References
Kinkel & Maloca (2009), Kinkel (2012), Canham &
Hamilton (2013), Kinkel (2014), Brennan et al.
(2015), Gylling et al. (2015), Fratocchi et al. (2016),
Robinson & Hsieh (2016), Stentoft et al. (2016a),
Stentoft et al. (2016b)
Kinkel & Maloca (2009), Kinkel (2012), Canham &
Hamilton (2013), Gray et al. (2013), Arlbjorn &
Mikkelsen (2014), Bailey & De Propris (2014a),
Bailey & De Propris (2014b), Kinkel (2014),
Ancarani et al. (2015), Brennan et al. (2015), Gylling
et al. (2015), Fratocchi et al. (2016), Joubioux &
Vanpouke (2016), Mlody (2016), Moradlou &
Backhouse (2016), Presley et al. (2016), Stentoft et
al. (2016a), Stentoft et al. (2016b) Zhai et al. (2016)
Kinkel & Maloca (2009), Kinkel (2012), Canham &
Hamilton (2013), Brennan et al. (2015), Mlody
(2016), Moradlou & Backhouse (2016), Robinson &
Hsieh (2016), Stentoft et al. (2016a)
Kinkel & Maloca (2009), Brennan et al. (2015),
Mlody (2016), Srai & Ane (2016)
Kinkel & Maloca (2009), Kinkel (2012), Canham &
Hamilton (2013), Kinkel (2014), Tate et al. (2014),
Brennan et al. (2015), Fratocchi et al. (2016), Srai &
Ane (2016), Stentoft et al. (2016a), White &
Borchers (2016), Zhai et al. (2016), Albertoni et al.
(2016)
Kinkel (2012), Canham & Hamilton (2013),
Martinez-Mora & Merino (2014), Ancarani et al.
(2015), Brennan et al. (2015), Fratocchi et al. (2016)
Kinkel (2012), Canham & Hamilton (2013), Ellram
et al. (2013), Bailey & De Propris (2014a), Kinkel
(2014), Tate (2014), Tate et al. (2014), Fratocchi et
al. (2016), Mlody (2016), Moradlou & Backhoue
(2016), Ocicka (2016), Robinson & Hsieh (2016),
Srai & Ane (2016), Stentoft et al. (2016a), White &
Borchers (2016), Zhai et al. (2016)

1

Flexibility

2

Quality

3

Coordination cost

4

Infrastructure

5

Availability of qualified
personnel

6

Ability to deliver on time

7

Labor cost

8

Monitoring cost

Kinkel (2012), Brennan et al. (2015)

9

Communication cost

Canham & Hamilton (2013), Srai & Ane (2016)

10

Logistics

Ellram et al. (2013), Bailey & De Propris (2014b),
White & Borchers (2016)

11

Switching cost

Ellram et al. (2013), White & Borchers (2016)
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12

13

14

Raw material
Country risk
(global/political
uncertainty,
environmental,
social/ethical, natural
disaster, regulation)
Government trade
policies (tax, trade
requirements)

Ellram et al. (2013), Srai & Ane (2016), White &
Borchers (2016)

Ellram et al. (2013), Presley et al. (2016), Srai &
Ane (2016), White & Borchers (2016)

Ellram et al. (2013) Joubioux & Vanpouke (2016)
Srai & Ane (2016) – political stability, natural
disaster White & Borchers (2016)

15

Tax rates

Gray et al. (2013), Tate et al. (2014)

16

Tariffs

Gray et al. (2013), Stentoft at al. (2016a)

17

Currency exchange

Ellram et al. (2013), Gray et al. (2013), Bailey & De
Propris (2014a), Tate et al. (2014), Joubioux &
Vanpouke (2016), Mlody (2016), Moradlou &
Backhoue (2016), Ocicka (2016), Srai & Ane (2016),
White & Borchers (2016)

18

Clusters/agglomeration

Gray et al. (2013)

19

Distance (cultural,
psychic, institutional)

20

Lead time

21

Automation

22

Focus on core activities

23

R&D

24

Logistics/Transportation
cost

25

Supply chain/supply
chain resilience

26

Cost (total)

Gray et al. (2013), Tate (2014), Mlody (2016) cultural Robinson & Hsieh (2016), Srai & Ane
(2016) – psychic
Arlbjorn & Mikkelsen (2014), Tate et al. (2014),
Joubioux & Vanpouke (2016), Robinson & Hsieh
(2016), Zhai et al. (2016)
Arlbjorn & Mikkelsen (2014), Tate (2014), Mlody
(2016), Srai & Ane (2016), Stentoft et al. (2016a),
Stentoft et al. (2016b), Zhai et al. (2016)
Arlbjorn & Mikkelsen (2014), Stentoft et al. (2016a)
Arlbjorn & Mikkelsen (2014), Kinkel (2014),
Brennan et al. (2015), Ashby (2016), Joubioux &
Vanpouke (2016), Robinson & Hsieh (2016), Srai &
Ane (2016), Stentoft et al. (2016a)
Bailey & De Propris (2014a), Kinkel (2014), Tate et
al. (2014), Brennan et al. (2015), Fratocchi et al.
(2016), Ocicka (2016), Robinson & Hsieh (2016),
Srai & Ane (2016), Stentoft et al. (2016a), Zhai et al.
(2016)
Bailey & De Propris (2014a), Bailey & De Propris
(2014b), Joubioux & Vanpouke (2016), Presley et al.
(2016), Srai & Ane (2016), Stentoft et al. (2016a),
Wiesmann et al. (2017)
Bailey & De Propris (2014b), Tate (2014), Ancarani
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et al. (2015), Abbasi (2016), Fratocchi et al. (2016),
Ocicka (2016), Robinson & Hsieh (2016), Stentoft et
al. (2016b), Zhai et al. (2016), Albertoni et al.
(2017), Kim et al. (2017)
Bailey & De Propris (2014b), Joubioux & Vanpouke
(2016)

27

Skilled workforce

28

Responses to customers

Bailey & De Propris (2014b), Tate (2014)

29

Technology

Bailey & De Propris (2014b), Gylling et al. (2015),
Ocicka (2016), Srai & Ane (2016)

30

Operations cost

Bailey & De Propris (2014b)

31

(Customer) services

32

Innovation

33

Turnover

Bailey & De Propris (2014b)

34

Coordination

Kinkel (2014)

35

Know-how

Kinkel (2014), Brennan et al. (2015), Srai & Ane
(2016), Stentoft et al. (2016a)

36

Proximity to home

Kinkel (2014)

37

Increase in domestic
production
(replenishments)

Martinez-Mora & Merino (2014)

38

Increase in new products

Martinez-Mora & Merino (2014)

39

Failure in market

Martinez-Mora & Merino (2014), Foerstl et al.
(2016), Albertoni et al. (2017)

40

CSR

Mezzadri (2014)

41
42

43

Bailey & De Propris (2014b), Ancarani et al. (2015),
Fratocchi et al. (2016), Srai & Ane (2016)
Bailey & De Propris (2014b), Tate (2014), Fratocchi
et al. (2016), Joubioux & Vanpouke (2016), Mlody
(2016), Robinson & Hsieh (2016), Albertoni et al.
(2017)

Surplus
warehouse/manufacturing Tate (2014)
space
Tate (2014), Mlody (2016), Moradlou & Backhouse
Productivity
(2016), Srai & Ane (2016), Stentoft et al. (2016a)
Tate (2014), Fratocchi et al. (2016), Joubioux &
Vanpouke (2016), Mlody (2016), Moradlou &
IP protection (risk)
Backhouse (2016), Ocicka (2016), Stentoft et al.
(2016a), Zhai et al. (2016)

44

Shipping requirement

Tate (2014)

45

Energy cost

Tate (2014), Tate et al. (2014), Moradlou &
Backhouse (2016), Ocicka (2016)
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46

Labor cost stability

Tate et al. (2014), White & Borchers (2016)

47

Transportation
availability

48

Proximity to customers

49

Made in effect

50

Government incentives

Tate et al. (2014), Mlody (2016), Moradlou &
Backhouse (2016)
Tate et al. (2014), Ancarani et al. (2015), Fratocchi
et al. (2016), Mlody (2016), Srai & Ane (2016),
Stentoft et al. (2016a)
Ancarani et al. (2015), Fratocchi et al. (2016), Mlody
(2016), Stentoft et al. (2016a)
Ancarani et al. (2015), Stentoft et al. (2016a), Zhai et
al. (2016)

51

Capacity utilization

Brennan et al. (2015), Fratocchi et al. (2016)

52

Import cost

Gylling et al. (2015)

53

Production cost

Gylling et al. (2015), Mlody (2016)

54

Cost competitiveness

Gylling et al. (2015)

55

Demand
fluctuation/volatility
(seasonality)

Gylling et al. (2015), Stentoft et al. (2016a)

56

Sourcing risk

Gylling et al. (2015)

57

Training contract
manufacturers

Gylling et al. (2015)

58

Growth of local economy

Ashby (2016)

59

Proximity to supplier

Ashby (2016)

60

Environmental
uncertainty

Forestl et al. (2016)

61

Relational issues

Forestl et al. (2016)

62

Asset specificity

Forestl et al. (2016)

63

Reorganization

Fratocchi et al. (2016)

64

Cost efficiency

Fratocchi et al. (2016)

65

Termination of supply
relationships

Fratocchi et al. (2016)

66

Minimum order size

Fratocchi et al. (2016)

67

Control complexity

Fratocchi et al. (2016), Zhai et al. (2016)

68

Subsides for relocation

Fratocchi et al. (2016)

69

Lack of local market
attractiveness

Fratocchi et al. (2016)

70

Counterfeiting

Fratocchi et al. (2016)
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71
72
73
74

Absence of local
suppliers
Customer duties for reimport
Unions’ pressure at the
home country
Adaptation to customer
needs & reliability

Fratocchi et al. (2016)
Fratocchi et al. (2016)
Fratocchi et al. (2016)
Joubioux & Vanpouke (2016)

75

Competitive advantage

Joubioux & Vanpouke (2016)

76

Unbeneficial legaladministrative conditions

Mlody (2016)

77

Investment incentives

Mlody (2016)

78

Proximity to market

Mlody (2016), Srai & Ane (2016)

79

Control cost

Mlody (2016), Robinson & Hsieh (2016)

80

Supply chain risk

81

Inventory

82

(extra) Management

83

Travel cost

Moradlou & Backhouse (2016)

84

Environmental
legislations

Moradlou & Backhouse (2016)

85

Communication

Moradlou & Backhouse (2016)

86

(Inter) cultural difference

Moradlou & Backhouse (2016)

87

Language barrier

Moradlou & Backhouse (2016)

88

Supply chain relationship

Ocicka (2016)

89

Environmental concern

Ocicka (2016), Presley et al. (2016), Srai & Ane
(2016), Zhai et al. (2016)

90

Lean supply chain

Ocicka (2016)

91

Supply chain disruption

Ocicka (2016)

92

NPV

Presley et al. (2016)

93

Company share value

Presley et al. (2016)

94

Coordination

Presley et al. (2016)

95

Reputation/image/brand

Presley et al. (2016), Zhai et al. (2016)

96

Local incentives

Srai & Ane (2016)

Mlody (2016), Stentoft et al. (2016a), White &
Bochers (2016)
Moradlou & Backhouse (2016), Srai & Ane (2016),
Zhai et al. (2016)
Moradlou & Backhouse (2016), Stentoft et al.
(2016b)
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97

Relationships/network

Srai & Ane (2016)

98

Economies of scale

Srai & Ane (2016)

99

Security

Srai & Ane (2016), Stentoft et al. (2016b)

100 Contract terms

Srai & Ane (2016)

101 Raw material cost

Srai & Ane (2016)

102 Administrative cost

Srai & Ane (2016)

103 Product development

Srai & Ane (2016)

Downsizing and
rationalization

Srai & Ane (2016)

104

105 Hidden cost

Srai & Ane (2016)

106 Vertical integration

Srai & Ane (2016)

Location branding for
traceability of the product
Location branding for
108
quality image
Location branding for
109
local social impact
Better traceability of
110
products
107

111 Actual cost
112

Production and delivery
reliability

Srai & Ane (2016)
Srai & Ane (2016)
Srai & Ane (2016)
Srai & Ane (2016)
Stentoft et al. (2016a)
Stentoft et al. (2016a)

113 Shrinking market size

Stentoft et al. (2016a)

114 Patriotism/loyalty

Stentoft et al. (2016a)

115

Correction of misjudged
decision

Stentoft et al. (2016a)

116 Bureaucracy

Stentoft et al. (2016b)

117 Production basis

Stentoft et al. (2016b)

118 Strategic access

White & Borchers (2016)

119 Response to demand

Zhai et al. (2016)

120 Lean manufacturing

Zhai et al. (2016)

121

Firm specific locational
advantage

122 Global competition

Delis et al. (2017)
Wiesmann et al. (2017)
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Appendix E. Codification of the interview responses
No.

Q3
- Deal with
patients
- Material
specification

Q4
- Quality and
regulation often go
hand in hand
- Regulation
designed to force
product to be
required quality
level
- Technology varies
- Quality and
regulation are
important and need
simultaneously
- Technology can
differ from company
to company
- Regulation has
more impact
because it forces to
meet the minimum
quality level

Q5
- Availability of raw
materials
- Environment
- Quality is most
important

Q6
- These do not
impact much

- Availability of raw
material
- Skilled workforce
- Regulatory assessment
process
- Environment

- All these
impact
location
decision

- Quality

n/a

- Technology
depends on the
complexity of
products

- Product specialization

n/a

- Not so much of
quality issues
currently
- Technology
depends on products
- Quality and
regulation especially
impact a lot on
manufacturing
process
- Quality matters
more than low labor
cost
- Quality matters;
regulation is
required

- Cost
- Tariffs (e.g. China)

- Product
specialization;
products and
location are
customerdriven
- It impacts
performance;
you can
provide the
product that
customers
want
- Tariffs can
affect price
changes

A

n/a

B

- It varies product
to product
C

D

E

F

- Higher quality
and regulatory
requirements

n/a
G
n/a
H
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- R&D cost
- Labor cost does not
impact a lot

- Availability and cost of
labor
- Availability of labor

- It impacts
performance;
technology
varies by
product type
- It impact net
profit
- It can impact
productivity
and capability

I

J

- Innovation
- Technology
- Serviceability
- Quality
standards
- Safety and
effectiveness

- Quality, regulation,
and technology all
have big impact on
firm performance
- Market review
process and
verification and
validation before
and after use by
FDA and other
country
requirements

- Cost (affordability –
price)
- Cost, quality,
regulation, and
technology together

- Highly
regulated
- Daunting
documentation
requirements
- Direct impact
on individuals
(death, severe
impairment
- Impact on
human being and
safety

- Quality and
regulation have
more impact than
technology

- Raw materials

- Quality and
regulation are highly
important e.g.
manufacturing
facilities in Europe
are investigated and
highly regulated by
EU
- Technology is
needed to the extent
it is sufficient to
manufacturing
products
- Quality is the most
important and
placed based on
customer demand
- Technology is easy
to transfer over the
borders

- Delivery (lead time)
- Timing
- Capacity

- Intellectual
property (IP)
- Labor cost
- Government
regulations
- Capacity
- Market
demand

- Customer demand

Manufacturing
cost
Transportation
cost

K

L

- Products
(drugs) are sold
in the location
that is approved
by healthcare
authority country
- Timing of
product
introduction is
critical
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- Proximity to
R&D
- Proximity to
customers
- Business
sustainability
(continuity of
operations)
- Better
perception
- Assurance of
product to
customers
- Technology
- Tax
incentive
- Raw material
(and
sterilization)

No.

Q7
- Cost
(transportation)

A

- Skilled
workforce
B

Q8
- Impact on the firm
performance in
regard to
environment, policy,
and cost
- Location matters to
firm performance
due to regulatory
process

Q9
With reshoring
- Price

With offshoring
- IP protection issues,
R&D in developing
economy (e.g. India) does
not work well, difficulty
in control
n/a

n/a

- Impact on product
quality

- Quality does not
have so much
impact on the
location decision

- Location does not
necessarily impact
on financial
performance

With offshoring
- Longer lead time
specified to customers,
With reshoring
- Cost, market
competition, good
customer perception

- Cost

- Location does not
impact a lot

- Quality
- R&D cost

- Location impacts
on profits and
availability of
specialized suppliers
and contract
manufacturers
- Location does not
impact a lot

With offshoring
- Currently not so much
of control or quality
issues
With offshoring
- Not so much of quality
issues because of the
required quality system
standards

C

D

E

F

G

- Labor cost
(manufacturing
labor intensive
products)

- Impact on
employee turnover
rate

H

I

- Supply chain
- Cost

- Impact on
productivity – cost,
quality, product, and
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With reshoring (domestic
operations)
- Obtaining high quality
and low cost labor is
difficult
With offshoring and
reshoring,
- Employee turnover
(keeping trained
employees)
With reshoring
- Business continuity
- Proximity to customers

Q10
- Product
development
process
(faster, better
control)
- Skilled
workforce

- Quality over
labor cost
(high labor
turnover rate
in foreign
locations)
- Product
specialization
- Expertise
- Factors are
not so much
market
oriented
(production
ability)
- Cost

- Production
specialization

- Quality
- Low labor
cost

- Availability
of labor
- Labor cost

- Core
competency

profit

- Better customer
perception
- Natural disaster

- Sourcing
(Production time,
expertise, low
cost)

- Minimal impact on
firm performance
- Can impact in
terms of government
tariffs

- Cost
Manufacturing
environment

- Quality

- Impact on the
supply chain

With offshoring
- Communication:
language barrier and time
difference
- Expertise
- Regulatory process
With reshoring
- Less communication
issue
- Better control
- Better regulatory
inspection access but
difficult process
With offshoring
- Being able to work with
government agencies e.g.
China
- Regulations are not
clear or established in
some locations
With reshoring
- Expertise is increased
- Reliability and
familiarity
- Better oversight
- Less quality concern
- Better security
- May lack production
capacity
- Increasing cost

- Demand
- Regulation

- Impact on cost
performance
because drug prices
are fixed by the
government in some
countries

With offshoring
- Availability and low
cost of raw material
- Increasing demand
- Low cost operation sites
With reshoring
- Rising demand in
neighboring countries e.g.
Canada, Mexico
- Tax benefits
- Import and export cost

- Demand
- Technology

J

K

L

- Increasing operating
cost
- Challenges to meet
global demand in one
location
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- IP
- Government
regulation
- Quality

Appendix F. Interview questions
1) Background (job title)
2) Company background (industry, primary products, etc.)
3) What are the distinct characteristics of medical devices or drugs compared to
other manufacturing industry sectors (e.g. automotive)?
4) How do quality, regulation, and technology impact decisions made in the
manufacturing process?
a. What is the regulation(s) that your company particularly has to deal
with if there is any?
5) What other factors affect medical device or drug manufacturing?
6) What are the roles of these factors in manufacturing location decision?
7) What are the factors considered the most and least important in this decision
and why?
8) How does manufacturing location impact on product or firm performance?
9) If currently offshored, what are the primary opportunities and/or challenges in
the current location and home country?
10) What are/would be the main criteria that affect location decision of your
company?
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Appendix G. Survey questions
1. Has your company reshored from the previous offshored region(s)?
a) Yes
b) No
c) I don’t know
2. Is your company currently considering reshoring part or all of your
manufacturing?
a) Yes
b) No
c) I don’t know
3. What is your job title in the company?
_______________________________________
4. Which of the following best describes your level in the company?
a) Owner/Director/CEO
b) Upper management (President, Vice president, etc.)
c) Middle management
d) Lower management/Supervisory
e) Technical
5. To what level do you participate in manufacturing decision making of your
company?
a) None b) Very low c) Low d) Intermediate

e) High

f) Very high

6. How many years of job experience do you have in the industry?
a) Less than 1 year
b) 1 – 5 years
c) 6 – 10 years
d) 11 – 15 years
e) 16 – 20 years
f) 20 years or more
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7. Does your company manufacture medical devices or drugs?
a) Medical devices only
b) Drugs and other pharmaceutical products only
c) Both medical devices and drugs
d) I don’t know
e) No, but we are involved in decision making related to manufacturing these
products (e.g. sales).
f) No, we are not involved in any of these products.
8. Please rate the following product characteristics of the primary product(s)
produced by your company.
Product complexity

a) very low b) low c) moderate d) high e) very high

Product standardization

a) very low b) low c) moderate d) high e) very high

Technology intensity

a) very low b) low c) moderate d) high e) very high

Labor intensity

a) very low b) low c) moderate d) high e) very high

9. Where does your company manufacture product(s)? Select all that apply.
a) U.S.
b) North America (non-U.S.)
c) South America
d) Asia
e) Europe
f) Africa
g) Others (Please specify.) ______________________
10. Where is the majority of your product(s) sold?
a)

U.S.

b)

North America (non-U.S.)

c)

South America

d)

Asia

e)

Europe

f)

Africa
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g)

Others (Please specify.) ______________________

11. What is the country where your company headquarters are located?
a) U.S.
b) Others (Please specify.) ____________________
12. What is the country of ownership of your company (home country)?
a)

U.S.

b)

Others (Please specify.) ____________________

13. What is the total number of employees in your company?
a) 0 – 9 employees
b) 10 – 49 employees
c) 50 – 249 employees
d) 250 – 499 employees
e) 500 – 999 employees
f) 1000 – 5000 employees
g) 5000 or more employees
14. Following are about factors that are involved in reshoring decisions. Please
rate each factor based on its impact on reshoring decisions in your company.
Items

Very
low

Low

Moderate

High

Very
high

Company share value
Infrastructure (e.g. transportation, logistics,
information systems, etc.)
Transportation cost

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Availability of raw materials

1

2

3

4

5

Proximity to suppliers
Ability to manage contract manufacturers
in offshored location(s)
Economies of scale (cost advantage
through a large volume of production)
Coordination and communication cost to
process information from/to manufacturing
in offshored location(s)

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Production cost (except labor) with
manufacturing in offshored location(s)
Import cost to/from offshored location(s)

1

2

3

4

5

1

2

3

4

5

Inventory management

1

2

3

4

5

Flexibility in manufacturing

1

2

3

4

5

Productivity

1

2

3

4

5

Level of product specialization

1

2

3

4

5

Proximity to market or customers
Customer perception of “Made in” home
country (e.g. USA) products
Lead time
Political risk (e.g. instability, regime
change, etc.) in offshored location(s)
Administrative conditions and cost in
offshored locations
Regulatory requirement for products
imported to or sold in home country (e.g.
FDA)
Government subsidies for relocation
Reponses to volatile demand in home
country
Government pressure to voluntarily
produce goods in home country
Environmental concerns (e.g. pollution) in
offshored location(s)
Supply chain disruptions
Lack of qualified labor in offshored
location(s)
Labor cost in offshored location(s)
Ability to control and coordinate with
manufacturing
Distance (physical distance and/or
perceived difference) with offshored
location(s)
Reorganization of the company (e.g.
downsizing)
Potential intellectual property (IP) theft in
offshored location(s)
Security in offshored location
Being able to automate manufacturing
process

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5
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Product quality in offshored location(s)
Research and development (R&D)
capability
R&D cost

1

2

3

4

5

1

2

3

4

5

1

2

3

4

5

Economic environment in home country

1

2

3

4

5

Industry clusters

1

2

3

4

5

Market competition

1

2

3

4

5

Currency exchange rate
Corporate social responsibility (CSR)
practice in offshored location(s)

1

2

3

4

5

1

2

3

4

5
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Appendix H. Classification of items through Q sort
No.

Items

Group

Variable

1

Company share value

A

CSV

2

Product complexity

A

n/a

3

Product standardization

A

n/a

4

Poor infrastructure (e.g. transportation, logistics,
information systems, etc.) in offshored location(s)

B

Infrastructure

5

High transportation cost in offshored location(s)

B

Infrastructure

6

Lack of raw materials in offshored location(s)

C

Supply

7

Proximity to suppliers

C

Supply

C

Supply

8
9
10
11

Requirement and management of contract
manufacturer in offshored location(s)
Economies of scale (cost advantage through a large
volume of production)
High coordination cost to process information
from/to manufacturing in offshored location(s)
High production cost (except labor) with
manufacturing in offshored location(s)

D
D
D

Cost
performance
Cost
performance
Cost
performance
Cost
performance
Cost
performance
Cost
performance
Cost
performance

12

High import cost to/from offshored location(s)

D

13

Difficulty in inventory management in offshored
location(s)

D

14

Low flexibility in offshored location(s)

D

15

Poor productivity in offshored locations

D

16

Customer requirement for product specialization

E

Customer

17

Proximity to market or customers

E

Customer

18

Customer perception of “Made in USA” products
and associated service

E

Customer

19

Long lead time from offshored location(s)

E

Customer

20

Political risk (instability) in offshored location(s)

F

21
22
23

Administrative conditions and cost in offshored
locations
Regulatory requirement for products imported to or
sold in home country (e.g. FDA)
Government subsidies for relocation
99

F
F
F

Market
condition
Market
condition
Market
condition
Market
condition

24
25
26

Reponses to volatile demand in home country
Government and customer pressure to produce goods
in home country
Environmental issues (e.g. natural disaster,
environmental sustainability) in offshored location(s)

G
G

Response to
demand
Response to
demand

H

n/a

27

Lack of qualified personnel in offshored location(s)

I

Labor

28

Increasing labor cost in offshored location(s)

I

Labor

29

Labor intensity

I

n/a

J

n/a

J

Management

J

n/a

J

n/a

J

Management

30
31
32
33
34

High communication cost with manufacturing in
offshored location(s)
Difficulty in control and coordination with
manufacturing in offshored location(s)
Corporate decision to downsize the company
Extra management needed for manufacturing and
supply chain in offshored location(s)
Distance (physical distance and/or perceived
difference) with offshored location(s)

35

Reorganization of the company

J

Management

36

Potential intellectual property (IP) theft in offshored
location(s)

K

Security

37

Security in offshored location

K

Security

38

Being able to automate manufacturing process

L

Automation

39

Technology intensity

L

n/a

40

Poor quality in offshored location(s)

M

Quality

41

High R&D cost associated with products

N

R&D

42

Unavailability of R&D and technology in offshored
location(s)

N

R&D

43

Unavailability of technology in offshored location(s)

N

n/a
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